Pharmacoeconomic evaluation of apixaban use for the treatment and prevention of venous thromboembolism in the general population and patients with oncological diseases

Συγγραφείς: A. S. Kolbin, A. R. Kasimova, S. R. Gilyarevskiy

Πηγή: Качественная клиническая практика, Vol 0, Iss 4, Pp 38-49 (2023)

Θεματικοί όροι: фармакоэкономический анализ, ишемический инсульт, апиксабан, венозные тромбоэмболические осложнения, дабигатран, прямые пероральные антикоагулянты, низкомолекулярные гепарины, 3. Good health, RS1-441, фибрилляция предсердий, Pharmacy and materia medica, ривароксабан, Medical technology, R855-855.5, тромбоэмболия лёгочной артерии, тромбоз глубоких вен, пероральные антикоагулянты

Σύνδεσμος πρόσβασης: https://doaj.org/article/6ff807e2571742b38079ad62f6a0f807

ОБЗОР КЛИНИЧЕСКОЙ ЭФФЕКТИВНОСТИ И БЕЗОПАСНОСТИ ПЕРОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ ПРЯМОГО ДЕЙСТВИЯ У ПАЦИЕНТОВ С МЕРЦАТЕЛЬНОЙ АРИТМИЕЙ В РЕАЛЬНЫХ КЛИНИЧЕСКИХ УСЛОВИЯХ

Συγγραφείς: Олимович, Норчаев Миржалол

Πηγή: SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES; Vol. 4 No. 3 (2025): SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES; 38-42 ; НАУЧНЫЙ ЖУРНАЛ ПРИКЛАДНЫХ И МЕДИЦИНСКИХ НАУК; Том 4 № 3 (2025): SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES; 38-42 ; 2181-3469

Θεματικοί όροι: фибрилляция предсердий, пероральные антикоагулянты, тромбоэмболические осложнения, инфаркт, инсульт

Περιγραφή αρχείου: application/pdf

Relation: https://sciencebox.uz/index.php/amaltibbiyot/article/view/13623/13783; https://sciencebox.uz/index.php/amaltibbiyot/article/view/13623

Διαθεσιμότητα: https://sciencebox.uz/index.php/amaltibbiyot/article/view/13623

АНТИТРОМБОТИЧЕСКАЯ ТЕРАПИЯ У ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ С ОСТРЫМ КОРОНАРНЫМ СИНДРОМОМ ПОСЛЕ ЧРЕСКОЖНОГО КОРОНАРНОГО ВМЕШАТЕЛЬСТВА. ОБЗОР ЛИТЕРАТУРЫ: ANTITHROMBOTIC THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION WITH ACUTE CORONARY SYNDROME AFTER PERCUTANEOUS CORONARY INTERVENTION. REVIEW

Πηγή: Наука и здравоохранение. :143-151

Θεματικοί όροι: пероральді антикоагулянттар, жедел коронарлық синдром, percutaneous coronary intervention, стенттеу, стентирование, stenting, p2y12 рецепторлар тежегіштері, жүрек қан тамырларына тері арқылы араласу, острый коронарный синдром, ингибиторы P2Y12 рецепторов, 3. Good health, acute coronary syndrome, жүрекше фибрилляциясы, фибрилляция предсердий, inhibitors of P2Y12 receptors, чрескожное коронарное вмешательство, atrial fibrillation, oral anticoagulants, пероральные антикоагулянты

Ten rules for oral anticoagulants prescription after a stroke ; 10 правил назначения пероральных антикоагулянтов после инсульта

Συγγραφείς: A. A. Kulesh, D. A. Demin, S. S. Kucherenko, А. А. Кулеш, Д. А. Дёмин, С. С. Кучеренко

Συνεισφορές: The investigation has not been sponsored, Исследование не имело спонсорской поддержки

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 16, No 4 (2024); 111-121 ; Неврология, нейропсихиатрия, психосоматика; Vol 16, No 4 (2024); 111-121 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2024-4

Θεματικοί όροι: апиксабан, oral anticoagulants, apixaban, пероральные антикоагулянты

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/2341/1709; https://nnp.ima-press.net/nnp/article/view/2341/1712; Seiffge DJ, Werring DJ, Paciaroni M, et al. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol. 2019 Jan;18(1):117-26. doi:10.1016/S1474-4422(18)30356-9. Epub 2018 Nov 8.; Кулеш АА, Демин ДА. Вопросы совершенствования ведения пациентов, перенесших ишемический инсульт на фоне фибрилляции предсердий. Неврология, нейропсихиатрия, психосоматика. 2022;14(6):115-21. doi:10.14412/2074-2711-2022-6-115-121; Diener HC, Hankey GJ. Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage: JACC Focus Seminar. J Am Coll Cardiol. 2020 Apr 21;75(15):1804-18. doi:10.1016/j.jacc.2019.12.072; Hart RG, Coull BM, Hart D. Early recurrent embolism associated with nonvalvular atrial fibrillation: a retrospective study. Stroke. 1983 Sep-Oct;14(5):688-93. doi:10.1161/01.str.14.5.688; Muscari A, Faccioli L, Lega MV, et al. Predicting hemorrhagic transformation and its timing from maximum cerebral lesion diameter in nonlacunar ischemic strokes. Brain Behav. 2020 Jan;10(1):e01497. doi:10.1002/brb3.1497. Epub 2019 Dec 17.; Кулеш АА. Чистая клиническая выгода (net clinical benefit) антикоагулянтной терапии с точки зрения невролога. Consilium Medicum. 2022;24(2):79-84. doi:10.26442/20751753.2022.2.201537; Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014 Mar 15;383(9921):955-62. doi:10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.; Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi:10.1056/NEJMoa1107039. Epub 2011 Aug 27.; Proietti M, Romanazzi I, Romiti GF, et al. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation : A Systematic Review and Meta-Analysis. Stroke. 2018 Jan;49(1):98-106. doi:10.1161/STROKEAHA.117.018395. Epub 2017 Nov 22.; Ray WA, Chung CP, Stein CM, et al. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation. JAMA. 2021 Dec 21;326(23):2395-404. doi:10.1001/jama.2021.21222; Connolly SJ, Eikelboom J, Joyner C, et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 Mar 3;364(9):806-17. doi:10.1056/NEJMoa1007432. Epub 2011 Feb 10.; Kamel H, Longstreth WT Jr, Tirschwell DL, et al; ARCADIA Investigators. Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial. JAMA. 2024 Feb 20;331(7):573-81. doi:10.1001/jama.2023.27188; Buckley BJR, Lane DA, Calvert P, et al. Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation : A Systematic Review and Meta-Analysis. J Clin Med. 2022 Jun 30;11(13):3788. doi:10.3390/jcm11133788; Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467. doi:10.1161/STR.0000000000000375. Epub 2021 May 24.; Joglar JA, Chung MK, Armbruster AL, et al; Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Jan 2;149(1):e1-e156. doi:10.1161/CIR.0000000000001193. Epub 2023 Nov 30.; Noubiap JJ, Nyaga UF, Ndoadoumgue AL, et al. Meta-Analysis of the Incidence, Prevalence, and Correlates of Atrial Fibrillation in Rheumatic Heart Disease. Glob Heart. 2020 May 18;15(1):38. doi:10.5334/gh.807; Vahanian A, Beyersdorf F, Praz F, et al; ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632. doi:10.1093/eurheartj/ehab395. Erratum in: Eur Heart J. 2022 Jun 1;43(21):2022. doi:10.1093/eurheartj/ehac051; Connolly SJ, Karthikeyan G, Ntsekhe M, et al; INVICTUS Investigators. Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation. N Engl J Med. 2022 Sep 15;387(11):978-88. doi:10.1056/NEJMoa2209051. Epub 2022 Aug 28.; Steffel J, Collins R, Antz M, et al; External reviewers. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021 Oct 9;23(10):1612-76. doi:10.1093/europace/euab065. Erratum in: Europace. 2021 Oct 9;23(10):1676. doi:10.1093/europace/euab157; Eikelboom JW, Connolly SJ, Brueckmann M, et al; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013 Sep 26;369(13):1206-14. doi:10.1056/NEJMoa1300615. Epub 2013 Aug 31.; Wang TY, Svensson LG, Wen J, et al. Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve. NEJM Evid. 2023 Jul;2(7):EVIDoa2300067. doi:10.1056/EVIDoa2300067. Epub 2023 May 6.; Alrohimi A, Jickling G, Buck B, Butcher KS. Timing of Anticoagulation after Acute Ischemic Stroke in Patients with Atrial Fibrillation. Can J Neurol Sci. 2023 Jul;50(4):503-14. doi:10.1017/cjn.2022.268; Kimura S, Toyoda K, Yoshimura S, et al; SAMURAI, RELAXED, RAF, RAF-NOAC, CROMIS-2, NOACISP LONGTERM, Erlangen Registry and Verona Registry Investigators. Practical “1-2-3-4-Day” Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study. Stroke. 2022 Feb 2:STROKEAHA121036695. doi:10.1161/STROKEAHA.121.036695. Epub 2022 Feb 2; Oldgren J, Asberg S, Hijazi Z, et al; National TIMING Collaborators. Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study. Circulation. 2022 Oct 4;146(14):1056-66. doi:10.1161/CIRCULATIONAHA.122.060666. Epub 2022 Sep 6.; Fischer U, Koga M, Strbian D, et al; ELAN Investigators. Early versus Later Anticoagulation for Stroke with Atrial Fibrillation. N Engl J Med. 2023 Jun 29;388(26):2411-21. doi:10.1056/NEJMoa2303048. Epub 2023 May 24.; Tirumandyam G, Krishna Mohan GV, Addi Palle LR, et al. Early Versus Delayed Oral Anticoagulation in Patients With Acute Ischemic Stroke Due to Atrial Fibrillation: A Meta-Analysis. Cureus. 2023 Jun 22;15(6):e40801. doi:10.7759/cureus.40801; Alrohimi A, Rose DZ, Burgin WS, et al. Risk of hemorrhagic transformation with early use of direct oral anticoagulants after acute ischemic stroke: A pooled analysis of prospective studies and randomized trials. Int J Stroke. 2023 Aug;18(7):864-72. doi:10.1177/17474930231164891. Epub 2023 Mar 26.; Goeldlin MB, Hakim A, Branca M, et al; ELAN Investigators. Early vs Late Anticoagulation in Minor, Moderate, and Major Ischemic Stroke With Atrial Fibrillation: Post Hoc Analysis of the ELAN Randomized Clinical Trial. JAMA Neurol. 2024 May 28:e241450. doi:10.1001/jamaneurol.2024.1450; Yasaka M, Koretsune Y, Yamashita T, et al. Recurrent Stroke and Bleeding Events after Acute Cardioembolic Stroke-Analysis Using Japanese Healthcare Database from Acute-Care Institutions. J Stroke Cerebrovasc Dis. 2018 Apr;27(4):1012-24. doi:10.1016/j.jstrokecerebrovasdis.2017.11.002. Epub 2017 Dec 12.; Кулеш АА, Янишевский СН, Демин ДА и др. Пациент с некардиоэмболическим ишемическим инсультом или транзиторной ишемической атакой высокого риска. Часть 1. Диагностика. Неврология, нейропсихиатрия, психосоматика. 2023;15(2):10-8. doi:10.14412/2074-2711-2023-2-10-18; Кулеш АА, Янишевский СН, Демин ДА и др. Пациент с некардиоэмболическим ишемическим инсультом или транзиторной ишемической атакой высокого риска. Часть 2. Вторичная профилактика. Неврология, нейропсихиатрия, психосоматика. 2023;15(3):4-10. doi:10.14412/2074-2711-2023-3-4-10; Yaghi S, Willey JZ, Cucchiara B, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Quality of Care and Outcomes Research. Treatment and Outcome of Hemorrhagic Transformation After Intravenous Alteplase in Acute Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2017 Dec;48(12):e343-e361. doi:10.1161/STR.0000000000000152. Epub 2017 Nov 2.; Tong X, Burgin WS, Ren Z, et al; ANGEL-ACT Study Group. Association of Stroke Subtype With Hemorrhagic Transformation Mediated by Thrombectomy Pass: Data From the ANGEL-ACT Registry. Stroke. 2022 Jun;53(6):1984-92. doi:10.1161/STROKEAHA.121.037411. Epub 2022 Mar 31.; Paciaroni M, Agnelli G, Corea F, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke. 2008 Aug;39(8):2249-56. doi:10.1161/STROKEAHA.107.510321. Epub 2008 Jun 5.; Vaclavik D, Vilionskis A, Jatuzis D, et al. Clinical outcome of cardioembolic stroke treated by intravenous thrombolysis. Acta Neurol Scand. 2018 Mar;137(3):347-55. doi:10.1111/ane.12880. Epub 2017 Dec 8.; Tian B, Tian X, Shi Z, et al; DIRECT-MT Investigators. Clinical and Imaging Indicators of Hemorrhagic Transformation in Acute Ischemic Stroke After Endovascular Thrombectomy. Stroke. 2022 May;53(5):1674-81. doi:10.1161/STROKEAHA.121.035425.; Sandset EC, Anderson CS, Bath PM, et al. European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. Eur Stroke J. 2021 Jun;6(2):XLVIII-LXXXIX. doi:10.1177/23969873211012133. Epub 2021 May 11.; Wang X, Minhas JS, Moullaali TJ, et al; ENCHANTED Investigators. Associations of Early Systolic Blood Pressure Control and Outcome After Thrombolysis-Eligible Acute Ischemic Stroke: Results From the ENCHANTED Study. Stroke. 2022 Mar;53(3):779-87. doi:10.1161/STROKEAHA.121.034580. Epub 2021 Oct 27.; Morris NA, Jindal G, Chaturvedi S. Intensive Blood Pressure Control After Mechanical Thrombectomy for Acute Ischemic Stroke. Stroke. 2023 May;54(5):1457-61. doi:10.1161/STROKEAHA.122.041949. Epub 2023 Apr 6.; Nishimoto T, Oka F, Okazaki K, Ishihara H. Timing of Direct Oral Anticoagulants for Hemorrhagic Transformation After Endovascular Treatment in Acute Ischemic Stroke. J Stroke Cerebrovasc Dis. 2022 Jul;31(7):106507. doi:10.1016/j.jstrokecerebrovasdis.2022.106507. Epub 2022 Apr 28.; Li L, Poon MTC, Samarasekera NE, et al. Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies. Lancet Neurol. 2021 Jun;20(6):437-47. doi:10.1016/S1474-4422(21)00075-2; Kuramatsu JB, Huttner HB. Management of oral anticoagulation after intracerebral hemorrhage. Int J Stroke. 2019 Apr;14(3):238-46. doi:10.1177/1747493019828555. Epub 2019 Feb 14.; Moon JY, Bae GH, Jung J, Shin DH. Restarting anticoagulant therapy after intracranial hemorrhage in patients with atrial fibrillation: A nationwide retrospective cohort study. Int J Cardiol Heart Vasc. 2022 Apr 26;40:101037. doi:10.1016/j.ijcha.2022.101037; Lin SY, Chang YC, Lin FJ, et al. Post-Intracranial Hemorrhage Antithrombotic Therapy in Patients With Atrial Fibrillation. J Am Heart Assoc. 2022 Mar 15;11(6):e022849. doi:10.1161/JAHA.121.022849. Epub 2022 Mar 4.; Greenberg SM, Ziai WC, Cordonnier C, et al; American Heart Association/American Stroke Association. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2022 Jul;53(7):e282-e361. doi:10.1161/STR.0000000000000407. Epub 2022 May 17.; Zhou Q, Liu X, Yang X, et al. Efficacy and safety of anticoagulation in atrial fibrillation patients with intracranial hemorrhage : A systematic review and meta-analysis. Front Pharmacol. 2023 Mar 9;14:1122564. doi:10.3389/fphar.2023.1122564; Wang X, Wen D, Chen Y, et al. Anticoagulation medication in nontraumatic intracranial hemorrhage survivors with atrial fibrillation. J Thromb Thrombolysis. 2023 Jul;56(1):1-11. doi:10.1007/s11239-023-02804-y. Epub 2023 Apr 6.; Кулеш АА. Современные подходы к диагностике при внутримозговом кровоизлиянии. Неврология, нейропсихиатрия, психосоматика. 2020;12(2):4-11. doi:10.14412/2074-2711-2020-2-4-11; Кулеш АА, Сыромятникова ЛИ. Терапия оральными антикоагулянтами у пациентов после внутримозгового кровоизлияния. Неврология, нейропсихиатрия, психосоматика. 2020;12(3):4-10. doi:10.14412/2074-2711-2020-3-4-10; Кулеш АА, Дробаха ВЕ, Шестаков ВВ. Церебральная спорадическая неамилоидная микроангиопатия: патогенез, диагностика и особенности лечебной тактики. Неврология, нейропсихиатрия, психосоматика. 2018;10(4):13-22. doi:10.14412/2074-2711-2018-4-13-22; Кулеш АА, Дробаха ВЕ, Шестаков ВВ. Церебральная болезнь мелких сосудов: классификация, клинические проявления, диагностика и особенности лечения. Неврология, нейропсихиатрия, психосоматика. 2019;11(3S):4-17. doi:10.14412/2074-2711-2019-3S-4-17; Новосадова ОА, Кулеш АА, Григорьева ВН. Диагностика церебральной амилоидной ангиопатии: на пути к Бостонским критериям 2.0. Российский неврологический журнал. 2020;25(5):4-13. doi:10.30629/2658-7947-2020-25-5-4-13; Duering M, Biessels GJ, Brodtmann A, et al. Neuroimaging standards for research into small vessel disease-advances since 2013. Lancet Neurol. 2023 Jul;22(7):602-18. doi:10.1016/S1474-4422(23)00131-X. Epub 2023 May 23.; Zanon Zotin MC, Makkinejad N, Schneider JA, et al. Sensitivity and Specificity of the Boston Criteria Version 2.0 for the Diagnosis of Cerebral Amyloid Angiopathy in a Community-Based Sample. Neurology. 2024 Jan 9;102(1):e207940. doi:10.1212/WNL.0000000000207940. Epub 2023 Dec 13.; Charidimou A, Boulouis G, Roongpiboonsopit D, et al. Cortical superficial siderosis and recurrent intracerebral hemorrhage risk in cerebral amyloid angiopathy: Large prospective cohort and preliminary meta-analysis. Int J Stroke. 2019 Oct;14(7):723-33. doi:10.1177/1747493019830065. Epub 2019 Feb 20.; Wu J, Liu Z, Yao M, et al. Clinical characteristics of cerebral amyloid angiopathy and risk factors of cerebral amyloid angiopathy related intracerebral hemorrhage. J Neurol. 2024 May 26. doi:10.1007/s00415-024-12451-9. Online ahead of print.; Soo Y, Zietz A, Yiu B, et al; Microbleeds International Collaborative Network. Impact of Cerebral Microbleeds in Stroke Patients with Atrial Fibrillation. Ann Neurol. 2023 Jul;94(1):61-74. doi:10.1002/ana.26642. Epub 2023 Apr 17.; Marti-Fabregas J, Camps-Renom P, Best JG, et al; Microbleeds International Collaborative Network (MICON). Stroke Risk and Antithrombotic Treatment During Follow-up of Patients With Ischemic Stroke and Cortical Superficial Siderosis. Neurology. 2023 Mar 21;100(12):e1267-e1281. doi:10.1212/WNL.0000000000201723. Epub 2022 Dec 19.; Kozberg MG, Perosa V, Gurol ME, van Veluw SJ. A practical approach to the management of cerebral amyloid angiopathy. Int J Stroke. 2021 Jun;16(4):356-69. doi:10.1177/1747493020974464. Epub 2020 Nov 29.; Merella P, Casu G, Chessa P, et al. When Atrial Fibrillation Meets Cerebral Amyloid Angiopathy: Current Evidence and Strategies. J Clin Med. 2023 Dec 15;12(24):7704. doi:10.3390/jcm12247704; Pennlert J, Overholser R, Asplund K, et al. Optimal Timing of Anticoagulant Treatment After Intracerebral Hemorrhage in Patients With Atrial Fibrillation. Stroke. 2017 Feb;48(2):314-20. doi:10.1161/STROKEAHA.116.014643. Epub 2016 Dec 20.; Nielsen PB, Larsen TB, Skjoth F, et al. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study. Circulation. 2015 Aug 11;132(6):517-25. doi:10.1161/CIRCULATIONAHA.115.015735. Epub 2015 Jun 9.; Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015 Feb 24;313(8):824-36. doi:10.1001/jama.2015.0846; Park YA, Uhm JS, Pak HN, et al. Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage. Heart Rhythm. 2016 Sep;13(9):1794-802. doi:10.1016/j.hrthm.2016.05.016; Kojima G. Frailty Defined by FRAIL Scale as a Predictor of Mortality : A Systematic Review and Meta-analysis. J Am Med Dir Assoc. 2018 Jun;19(6):480-3. doi:10.1016/j.jamda.2018.04.006; Desai R, Li A, Mondal A, et al. Direct Oral Anticoagulants Versus Vitamin K Antagonist (Warfarin) For Stroke Prevention In Frail Patients With Atrial Fibrillation: A Meta-Analysis. Proc (Bayl Univ Med Cent). 2022 Dec 22;36(2):274-5. doi:10.1080/08998280.2022.2155926; Grymonprez M, Petrovic M, De Backer TL, et al. Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J Qual Care Clin Outcomes. 2024 Jan 12;10(1):55-65. doi:10.1093/ehjqcco/qcad019; Galvain T, Hill R, Donegan S, et al. Efficacy and Safety of Anticoagulants in Patients with Atrial Fibrillation and History of Falls or Risk of Falls : A Systematic Review and Multilevel Meta-Analysis. Drug Saf. 2022 Nov;45(11):1349-62. doi:10.1007/s40264-022-01231-x. Epub 2022 Sep 19.; Lip GYH, Keshishian A, Li X, et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2018 Dec;49(12):2933-44. doi:10.1161/STROKEAHA.118.020232; Bonanad C, Formiga F, Anguita M, et al. Oral Anticoagulant Use and Appropriateness in Elderly Patients with Atrial Fibrillation in Complex Clinical Conditions: ACONVENIENCE Study. J Clin Med. 2022 Dec 14;11(24):7423. doi:10.3390/jcm11247423; Парфенов ВА, Кулеш АА. Цереброваскулярное заболевание с когнитивными нарушениями. Журнал неврологии и психиатрии им. С.С. Корсакова. 2021;121(9):121-30. doi:10.17116/jnevro2021121091121; Кулеш АА, Емелин АЮ, Боголепова АН и др. Клинические проявления и вопросы диагностики хронического цереброваскулярного заболевания (хронической ишемии головного мозга) на ранней (додементной) стадии. Неврология, нейропсихиатрия, психосоматика. 2021;13(1):4-12. doi:10.14412/2074-2711-2021-1-4-12; Madhavan M, Graff-Radford J, Piccini JP, Gersh BJ. Cognitive dysfunction in atrial fibrillation. Nat Rev Cardiol. 2018 Dec;15(12):744-56. doi:10.1038/s41569-018-0075-z; Lin KJ, Singer DE, Bykov K, et al. Comparative Effectiveness and Safety of Oral Anticoagulants by Dementia Status in Older Patients With Atrial Fibrillation. JAMA Netw Open. 2023 Mar 1;6(3):e234086. doi:10.1001/jamanetworkopen.2023.4086; Grymonprez M, Petrovic M, De Backer TL, et al. Comparing the risk of dementia in subjects with atrial fibrillation using non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists: a Belgian nationwide cohort study. Age Ageing. 2023 Mar 1;52(3):afad038. doi:10.1093/ageing/afad038; Luca F, Oliva F, Abrignani MG, et al. Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios. J Clin Med. 2023 Sep 13;12(18):5955. doi:10.3390/jcm12185955; Paciaroni M, Agnelli G, Caso V, et al. Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. Stroke. 2019 Aug;50(8):2168-74. doi:10.1161/STROKEAHA.119.025350. Epub 2019 Jun 25.; Katsi V, Georgiopoulos G, Skafida A, et al. Noncardioembolic Stroke in Patients with Atrial Fibrillation. Angiology. 2019 Apr;70(4):299-304. doi:10.1177/0003319718791711. Epub 2018 Jul 31.; Ip YMB, Lau KK, Ko H, et al. Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant. Neurology. 2023 Jul 25;101(4):e358-e369. doi:10.1212/WNL.0000000000207422. Epub 2023 May 24.; Deitelzweig S, Kang A, Jiang J, et al. Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation. J Clin Med. 2024 Feb 14;13(4):1073. doi:10.3390/jcm13041073; Healey JS, Eikelboom J, Douketis J, et al; RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012 Jul 17;126(3):343-8. doi:10.1161/CIRCULATIONAHA.111.090464. Epub 2012 Jun 14.; Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med. 2019 Nov 1;179(11):1469-78. doi:10.1001/jamainternmed.2019.2431; Liu X, Huang M, Ye C, et al. Effect of non-recommended doses versus recommended doses of direct oral anticoagulants in atrial fibrillation patients: A meta-analysis. Clin Cardiol. 2021 Apr;44(4):472-80. doi:10.1002/clc.23586. Epub 2021 Mar 7.; Ashraf H, Agasthi P, Shanbhag A, et al. Long-Term Clinical Outcomes of Underdosed Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Atrial Flutter. Am J Med. 2021 Jun;134(6):788-96. doi:10.1016/j.amjmed.2020.12.022. Epub 2021 Jan 12.

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/2341
https://doi.org/10.14412/2074-2711-2024-4-111-121

Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19

Συγγραφείς: V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev

Πηγή: Качественная клиническая практика, Vol 0, Iss 4S, Pp 18-22 (2020)

Θεματικοί όροι: RS1-441, 2. Zero hunger, 03 medical and health sciences, Pharmacy and materia medica, 0302 clinical medicine, covid-19, Medical technology, коронавирус, прямые пероральные антикоагулянты, R855-855.5, 3. Good health

Σύνδεσμος πρόσβασης: https://www.clinvest.ru/jour/article/download/519/527
https://doaj.org/article/c642c348f7d74c5f821007ddf6ae9220
https://www.clinvest.ru/jour/article/download/519/527
https://www.clinvest.ru/jour/article/view/519
https://cyberleninka.ru/article/n/vozmozhnost-primeneniya-pryamyh-peroralnyh-antikoagulyantov-dlya-profilaktiki-tromboembolicheskih-sobytiy-u-patsientov-s-covid-19
https://cyberleninka.ru/article/n/vozmozhnost-primeneniya-pryamyh-peroralnyh-antikoagulyantov-dlya-profilaktiki-tromboembolicheskih-sobytiy-u-patsientov-s-covid-19/pdf

Efficacy and safety of direct oral anticoagulants in children in real clinical practice ; Эффективность и безопасность применения прямых пероральных антикоагулянтов у детей в реальной клинической практике

Συγγραφείς: T. Yu. Yafoshkina, Yu. A. Shifrin, D. V. Fedorova, D. B. Florinskiy, D. A. Evstratov, P. A. Zharkov, Т. Ю. Яфошкина, Ю. А. Шифрин, Д. В. Федорова, Д. Б. Флоринский, Д. А. Евстратов, П. А. Жарков

Πηγή: Russian Journal of Pediatric Hematology and Oncology; Том 10, № 1 (2023); 33-40 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 10, № 1 (2023); 33-40 ; 2413-5496 ; 2311-1267

Θεματικοί όροι: новые пероральные антикоагулянты, thrombosis therapy, thrombosis in children, anticoagulants, new oral anticoagulants, терапия тромбозов, тромбозы у детей, антикоагулянты

Περιγραφή αρχείου: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/919/813; Raffini L., Huang Y.S., Witmer C., Feudtner C. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics. 2009;124(4):1001–8. doi:10.1542/peds.2009-0768.; Федеральные клинические рекомендации по диагностике, профилактике и лечению тромбозов у детей и подростков. М., 2015.; [Электронный ресурс]. URL: https://www.uptodate.com/contents/venous-thrombosis-and-thromboembolism-vte-in-children-riskfactors-clinical-manifestations-and-diagnosis. (Дата обращения: 14.09.2022).; De Crem N., Peerlinck K., Vanassche T., Vanheule K., Debaveye B., Middeldorp S., Verhamme P., Peetermans M. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thromb Res. 2015;136(4):749–53. doi:10.1016/j.thromres.2015.07.030.; Kaatz S., Ahmad D., Spyropoulos A.C., Schulman S.; Subcommittee on Control of Anticoagulation. Definition of clinically relevant nonmajor bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119–26. doi:10.1111/jth.13140.; [Электронный ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=073cdf44-10f6-4fa4-ab24-a5727d8c90f5. (Дата обращения: 17.01.2023).; Halton J., Brandão L.R., Luciani M., Bomgaars L., Chalmers E., Mitchell L.G., Nurmeev I., Sharathkumar A., Svirin P., Gorbatikov K., Tartakovsky I., Simetzberger M., Huang F., Sun Z., Kreuzer J., Gropper S., Reilly P., Brueckmann M., Albisetti M.; DIVERSITY Trial Investigators. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol. 2021;8(1):e22–33. doi:10.1016/S2352-3026(20)30368-9.; Male C., Lensing A.W.A., Palumbo J.S., Kumar R., Nurmeev I., Hege K., Bonnet D., Connor P., Hooimeijer H.L., Torres M., Chan A.K.C., Kenet G., Holzhauer S., Santamaría A., Amedro P., Chalmers E., Simioni P., Bhat R.V., Yee D.L., Lvova O., BeyerWestendorf J., Biss T.T., Martinelli I., Saracco P., Peters M., Kállay K., Gauger C.A., Massicotte M.P., Young G., Pap A.F., Majumder M., Smith W.T., Heubach J.F., Berkowitz S.D., Thelen K., Kubitza D., Crowther M., Prins M.H., Monagle P.; EINSTEIN-Jr Phase 3 Investigators. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020;7(1):e18–27. doi:10.1016/S2352-3026(19)30219-4.; Bryk A.H., Piróg M., Plens K., Undas A. Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism. Vascul Pharmacol. 2016;87:242–7. doi:10.1016/j.vph.2016.11.003.; Bannow B.S. Management of heavy menstrual bleeding on anticoagulation. Hematology Am Soc Hematol Educ Program. 2020;2020(1):533–7. doi:10.1182/hematology.2020000138.; Limperger V., Torge A., Kiesau B., Langer F., Kenet G., Mesters R., Juhl D., Stoll M., Shneyder M., Kowalski D., Bajorat T., Rocke A., Kuta P., Lasarow L., Spengler D., Junker R., Nowak-Göttl U. Validation of a predictive model for identifying an increased risk for recurrence in adolescents and young adults with a first provoked thromboembolism. Blood Cells Mol Dis. 2022;94:102651. doi:10.1016/j.bcmd.2022.102651.; Brandão L.R., Albisetti M., Halton J., Bomgaars L., Chalmers E., Mitchell L.G., Nurmeev I., Svirin P., Kuhn T., Zapletal O., Tartakovsky I., Simetzberger M., Huang F., Sun Z., Kreuzer J., Gropper S., Brueckmann M., Luciani M.; DIVERSITY Study Investigators. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood. 2020;135(7):491–504. doi:10.1182/blood.2019000998.; Pinchinat A., Otero N., Mahanti H., Morris E., Brudnicki A., Friedman D., Li S., Levendoglu-Tugal O., Cairo M.S.; A Pilot Study of an Oral Anticoagulant, Apixaban, in Secondary Prophylaxis of Venous Thromboembolism (VTE) in Children and Adolescents. Blood. 2019;134(Suppl. 1):2443. doi:10.1182/blood-2019-130468.; O’Brien S., Rodriguez V., Lew G., Newburger J., Schultz C., Orgel E., Derr K., Ranalli M., Esbenshade A., Hochberg J., Kang H., Dinikina Y., Crevar C., Donovan M., Dyme J., Favatella N., Mitchell L. PREVAPIX-ALL: Phase 3 Study of the Safety and Efficacy of Apixaban for Thromboprophylaxis versus Standard of Care in Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia or Lymphoma (ALL/LL). [Электронный ресурс]. URL: https://abstracts.isth.org/abstract/prevapix-all-phase-3-study-of-the-safety-and-efficacy-ofapixaban-for-thromboprophylaxis-versus-standard-of-care-in-newlydiagnosed-pediatric-acute-lymphoblastic-leukemia-or-lymphoma-all-ll/. Accessed January 23, 2023.; McCrindle B.W., Michelson A.D., Van Bergen A.H., Horowitz E.S., Sandoval J.P., Justino H., Harris K.C., Jefferies J.L., Pina L.M., Peluso C., Nessel K., Lu W., Li J.S.; UNIVERSE Study Investigators. Thromboprophylaxis for children post-Fontan procedure: insights from the UNIVERSE study. J Am Heart Assoc. 2021;10(22):e021765. doi:10.1161/JAHA.120.021765.; Nowak-Göttl U., Junker R., Kreuz W., von Eckardstein A., Kosch A., Nohe N., Schobess R., Ehrenforth S.; Childhood Thrombophilia Study Group. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood. 2001;97(4):858–62. doi:10.1182/blood.v97.4.858.; Goldenberg N.A., Pounder E., Knapp-Clevenger R., Manco-Johnson M.J. Validation of upper extremity post-thrombotic syndrome outcome measurement in children. J. Pediatr. 2010;157(5):852–5. doi:10.1002/rth2.12251.; Goldenberg N.A., Donadini M.P., Kahn S.R., Crowther M., Kenet G., Nowak-Göttl U., Manco-Johnson M.J. Post-thrombotic syndrome in children: a systematic review of frequency of occurrence, validity of outcome measures, and prognostic factors. Haematologica. 2010;95(11):1952–9. doi:10.3324/haematol.2010.026989.; Avila M.L., Feldman B.M., Pullenayegum E., Lumia C., Montoya M.I., Vincelli J., Williams S., Brandão L.R. Post-thrombotic syndrome in children: Measurement properties of CAPTSure, a new diagnostic tool. Res Pract Thromb Haemost. 2019;3(4):652–7. doi:10.1002/rth2.12251.; https://journal.nodgo.org/jour/article/view/919

Διαθεσιμότητα: https://journal.nodgo.org/jour/article/view/919
https://doi.org/10.21682/2311-1267-2023-10-1-33-40

New prospects for assessing the hemostasis system in atrial fibrillation and left atrial appendage thrombosis ; Возможности оценки системы гемостаза при фибрилляции предсердий и тромбозе ушка левого предсердия

Συγγραφείς: Z. A. Gebekova, I. I. Ivanov, A. A. Kudrjavtseva, E. V. Kolpachkova, A. A. Sokolova, V. P. Sedov, D. A. Napalkov, З. А. Гебекова, И. И. Иванов, А. А. Кудрявцева, Е. В. Колпачкова, А. А. Соколова, В. П. Седов, Д. А. Напалков

Πηγή: Aterotromboz = Atherothrombosis; Том 12, № 2 (2022); 103-112 ; Атеротромбоз; Том 12, № 2 (2022); 103-112 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2022-2

Θεματικοί όροι: дабигатран, atrial fibrillation (AF), left atrial thrombosis, direct oral anticoagulants (DOACs), dabigatran, фибрилляция предсердий, тромбоз левого предсердия, прямые пероральные антикоагулянты

Περιγραφή αρχείου: application/pdf

Relation: https://www.aterotromboz.ru/jour/article/view/289/302; Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J., Blomström-Lundqvist C. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612.; Durmaz E., Karpuz M.H., Bilgehan K., Ikitimur B., Ozmen E., Ebren C. et al. Left atrial thrombus in patients with atrial fibrillation and under oral anticoagulant therapy; 3-D transesophageal echocardiographic study. Int J Cardiovasc Imaging. 2020;36(6):1097–1103. https://doi.org/10.1007/s10554-020-01811-x.; Göldi T., Krisai P., Knecht S., Aeschbacher S., Spies F., Zeljkovic I. et al. Prevalence and Management of Atrial Thrombi in Patients With Atrial Fibrillation Before Pulmonary Vein Isolation. JACC Clin Electrophysiol. 2019;5(12):1406–1414. https://doi.org/10.1016/j.jacep.2019.09.003.; Кривошеев Ю.С., Башта Д.И., Красильникова С.Ю., Виленский Л.И., Колесников В.Н., Чуков С.З., Романов А.Б. Тромбоз ушка левого предсердия при фибрилляции предсердий – современное состояние проблемы. Вестник аритмологии. 2019;26(4):13–20. https://doi.org/10.35336/VA-2019-4-13-20.; Гебекова З.А., Иванов И.И., Асамбаева А., Скрипка А.И., Соколова А.А., Напалков Д.А., Вуймо Т.А. Тест «Тромбодинамика» в оценке риска тромбообразования у пациентов с фибрилляцией предсердий, получающих прямые оральные антикоагулянты. Рациональная фармакотерапия в кардиологии. 2022;18(5):544–552. https://doi.org/10.20996/1819-6446-2022-09-07.; Kolekar S., Munjewar Ch., Sharma S. Dabigatran for left ventricular thrombus. Indian Heart Journal. 2015;67:495–496. https://doi.org/10.1016/j.ihj.2015.06.010.; Vidal A., Vanerio G. Dabigatran and left atrial appendage thrombus. J Thromb Thrombolysis. 2012;34:545–547. https://doi.org/10.1007/s11239-012-0747-1.; Takasugi J., Yamagami H., Okata T., Toyoda K., Nagatsuka K. Dissolution of the Left Atrial Appendage Thrombus with Rivaroxaban Therapy. Cerebrovasc Dis. 2013;36:322–323. https://doi.org/10.1159/000354315.; Hammerstingl C., Pötzsch B., Nickenig G. Resolution of giant left atrial appendage thrombus with rivaroxaban. Thromb Haemost. 2013;109:583–584. https://doi.org/10.1160/TH12-11-0821.; Kawakami T., Kobayakawa H., Ohno H., Tanaka N., Ishihara H. Resolution of left atrial appendage thrombus with apixaban. Thromb J. 2013;11(1):26. https://doi.org/10.1186/1477-9560-11-26.; Yildirim E., Kalkan K., Ipek E., Demirelli S., Ermiş E. Successful resolution of left ventricular thrombus with apixaban treatment. Int J Cardiovasc Acad. 2016;2(2):57–58. https://doi.org/10.1016/j.ijcac.2015.12.004.; Lip G.Y., Hammerstingl C., Marin F., Cappato R., Meng I.L., Kirsch B. et al. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2016;178:126–134. https://doi.org/10.1016/j.ijcac.2015.12.004.; Zoppo F., Brandolino G., Berton A., Frigato N., Michieletto M., Zanocco A. et al. Predictors of left atrium appendage clot detection despite on-target warfarin prevention for atrial fibrillation. J Interv Card Electrophysiol. 2012;35(2):151–158. https://doi.org/10.1007/s10840-012-9707-0.; Кропачева Е.С., Панченко Е.П., Добровольский А.Б., Атауллаханова А.М., Быкова Е.С., Титаева Е.В., Атьков О.Ю. Длительная терапия непрямыми антикоагулянтами у больных с мерцательной аритмией без поражения клапанов сердца (проспективное наблюдение). Часть I. влияние 12-месячной терапии аценокумаролом на уровень Д-димера, частоту тромбоза и параметры гемодинамики в ушке левого предсердия. Кардиология. 2004;44(6):19–25. Режим доступа: https://pubmed.ncbi.nlm.nih.gov/15211343.; Kawabata M., Goya M., Sasaki T., Maeda S., Shirai Y., Nishimura T. et al. Left Atrial Appendage Thrombi Formation in Japanese Non-Valvular Atrial Fibrillation Patients During Anticoagulation Therapy – Warfarin vs. Direct Oral Anticoagulants. Circ J. 2017;81(5):645–651. https://doi.org/10.1253/circj.CJ-16-1089.; Баландина А.Б., Кольцова Е.М., Шибеко А.М., Купраш А.Д., Атауллаханов Ф.И. Тромбодинамика: новый подход к диагностике нарушений системы гемостаза. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2018;17(4):114–126. https://doi.org/10.24287/1726-1708-2018-17-4-114-126.; Vuimo T., Belikov E., Litinskaya O. Efficiency of Thrombodynamics for Analysis of Hemostasis in Case of Transitory Ischemic Attack after Radio-frequency Ablation in a Patient with Paroxysmal Atrial Fibrillation. Am J Med Case Rep. 2015;3(10):333–337. https://doi.org/10.12691/ajmcr-3-10-8.; Balandina A.N., Serebriyskiy I.I., Poletaev A.V., Polokhov D., Gracheva M., Koltsova E. et al. Thrombodynamics-A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment. PloS ONE. 2018;13(6):е0199900. https://doi.org/10.1371/journal.pone.0199900.; Sinauridze E.I., Vuimo T.A., Tarandovskiy I.D., Ovsepyan R., Surov S., Korotina N. et al. Thrombodynamics, a new global coagulation test: Measurement of heparin efficiency. Talanta. 2018;180:282–291. https://doi.org/10.1016/j.talanta.2017.12.055.; Рубаненко А.О., Рубаненко О.А., Дьячков В.А., Щукин Ю.В. Роль D-димера в прогнозировании риска инсульта у больных с фибрилляцией предсердий. Гематология и трансфузиология. 2022;67(2):261–266. https://doi.org/10.35754/0234-5730-2022-67-2-261-266.; https://www.aterotromboz.ru/jour/article/view/289

Διαθεσιμότητα: https://www.aterotromboz.ru/jour/article/view/289
https://doi.org/10.21518/2307-1109-2022-12-2-103-112

Anticoagulant therapy for pulmonary embolism in cancer patients

Πηγή: Лекарства Украины; № 7(263) (2022); 20-28
Medicine of Ukraine; No. 7(263) (2022); 20-28
Ліки України; № 7(263) (2022); 20-28

Θεματικοί όροι: tumors, онкологія, онкология, пероральні антикоагулянти, thromboembolism, тромбоемболія, низкомолекулярные гепарины, 3. Good health, пухлини, oncology, низькомолекулярні гепарини, oral anticoagulants, опухоли, low molecular weight heparins, тромбоэмболия, пероральные антикоагулянты

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: http://lu-journal.com.ua/article/view/271777

Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art ; Клинически значимые лекарственные взаимодействия прямых пероральных антикоагулянтов: современное состояние вопроса

Συγγραφείς: S. R. Gilyarevsky, С. Р. Гиляревский

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 18, No 3 (2022); 332-341 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 3 (2022); 332-341 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: дабигатран, direct oral anticoagulants, apixaban, rivaroxaban, dabigatran, прямые пероральные антикоагулянты, апиксабан, ривароксабан

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2756/2322; Sarah S. The pharmacology and therapeutic use of dabigatran etexilate. J Clin Pharmacol. 2013;53(1):113. DOI:10.1177/0091270011432169.; Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6(5):820-9. DOI:10.1111/j.15387836.2008.02939.x.; Chan NC, Hirsh J, Ginsberg JS, Eikelboom JW. Betrixaban (PRT054021): pharmacology, dose selection and clinical studies. Future Cardiol. 2014;10(1):43-52. DOI:10.2217/fca.13.98.; Corsini A, Ferri N, Proietti M, Boriani G. Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. Drugs. 2020;80(11):1065-83. DOI:10.1007/s40265-020-01328-6.; Kvasnicka T, Malikova I, Zenahlikova Z, et al. Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions. Curr Drug Metab. 2017;18(7):636-42. DOI:10.2174/1389200218666170518165443.; Foerster KI, Hermann S, Mikus G, Haefeli WE. Drug-Drug Interactions with Direct Oral Anticoagulants. Clin Pharmacokinet. 2020;59(8):967-80. DOI:10.1007/s40262-020-00879-x.; Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131-41. DOI:10.1056/NEJMoa1607887.; Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med. 2017;377(5):431-41. DOI:10.1056/NEJMoa1707278.; Reilly PA, Lehr T, Haertter S, et al.; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63(4):321-8. DOI:10.1016/j.jacc.2013.07.104.; Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2288-95. DOI:10.1016/S0140-6736(14)61943-7.; Herink MC, Zhuo YF, Williams CD, DeLoughery TG. Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs). Drugs. 2019;79(15):1625-34. DOI:10.1007/s40265-019-01183-0.; Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. DOI:10.1056/NEJMoa0905561. Erratum in: N Engl J Med. 2010;363(19):1877.; Granger CB, Alexander JH, McMurray JJ, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. DOI:10.1056/NEJMoa1107039.; Giugliano RP, Ruff CT, Braunwald E, et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104. DOI:10.1056/NEJMoa1310907.; Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. DOI:10.1056/NEJMoa1009638.; Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633-641. DOI:10.1160/th10-01-0066.; Leil TA, Feng Y, Zhang L, et al. Quantification of apixaban’s therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin Pharmacol Ther. 2010;88(3):375-382. DOI:10.1038/clpt.2010.106.; Sakaguchi T, Osanai H, Murase Y, et al. Monitoring of anti-Xa activity and factors related to bleeding events: a study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban. J Cardiol. 2017;70(3):244-9. DOI:10.1016/j.jjcc.2016.11.013.; Carnicelli AP, Hong H, Connolly SJ, et al.; COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) Investigators. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network MetaAnalyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation. 2022;145(4):242-55. DOI:10.1161/CIRCULATIONAHA.121.056355.; Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962. DOI:10.1016/S0140-6736(13)62343-0.; Almutairi AR, Zhou L, Gellad WF, et al. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. Clin Ther. 2017;39(7):1456-78.e36. DOI:10.1016/j.clinthera.2017.05.358.; Piccini JP, Hellkamp AS, Washam JB, et al. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Circulation. 2016;133(4):352-60. DOI:10.1161/CIRCULATIONAHA.115.018544.; Focks JJ, Brouwer MA, Wojdyla DM, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016;353:i2868. DOI:10.1136/bmj.i2868.; Harskamp RE, Teichert M, Lucassen WAM, et al. Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation. Cardiovasc Drugs Ther. 2019;33(5):615-23. DOI:10.1007/s10557-019-06907-8.; Stöllberger C, Finsterer J. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Herz. 2015;40 Suppl 2:140-5. DOI:10.1007/s00059-014-4188-9.; Chang SH, Chou IJ, Yeh YH, et al. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. JAMA. 2017;318(13):1250-9. DOI:10.1001/jama.2017.13883.; Rodrigues AD. Prioritization of clinical drug interaction studies using in vitro cytochrome P450 data: proposed refinement and expansion of the "rank order" approach. Drug Metab Lett. 2007;1(1):31-5. DOI:10.2174/187231207779814247.; Wiggins BS, Dixon DL, Neyens RR, et al. Select Drug-Drug Interactions With Direct Oral Anticoagulants. J Am Coll Cardiol. 2020;75:1341-50. DOI:10.1016/j.jacc.2019.12.068.; Cheong EJY, Goh JJN, Hong Y, et al. Rivaroxaban With and Without Amiodarone in Renal Impairment. J Am Coll Cardiol. 2018;71(12):1395-7. DOI:10.1016/j.jacc.2018.01.044.; Flaker G, Lopes RD, Hylek E, et al.; ARISTOTLE Committees and Investigators. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol. 2014;64(15):1541-50. DOI:10.1016/j.jacc.2014.07.967.; Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2015;36(33):2239-45. DOI:10.1093/eurheartj/ehv201.; Steinberg BA, Hellkamp AS, Lokhnygina Y, et al.; ROCKET AF Steering Committee and Investigators. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. Heart Rhythm. 2014;11(6):925-32. DOI:10.1016/j.hrthm. 2014.03.006.; Friberg L. Safety of apixaban in combination with dronedarone in patients with atrial fibrillation. Int J Cardiol. 2018;264:85-90. DOI:10.1016/j.ijcard.2018.02.055.; Härtter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol. 2013;75(4):1053-62. DOI:10.1111/j.1365-2125.2012.04453.x.; Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75(2):47687. DOI:10.1111/j.1365-2125.2012.04369.x.; Kim M, Son H, Noh K, et al. Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban. Pharmaceutics. 2019;11(3):133. DOI:10.3390/pharmaceutics11030133.; Greenblatt DJ, Patel M, Harmatz JS, et al. Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection. J Clin Pharmacol. 2018;58(4):533-540. DOI:10.1002/jcph.1040.; Bartlett JW, Renner E, Mouland E, et al. Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and Diltiazem. Ann Pharmacother. 2019;53(1):21-7. DOI:10.1177/1060028018795140.; Wiggins BS, Northup A, Johnson D, Senfield J. Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin. Pharmacotherapy. 2016;36(2):e5-7. DOI:10.1002/phar.1698.; King PK, Stump TA, Walkama AM, et al. Management of Phenobarbital and Apixaban Interaction in Recurrent Cardioembolic Stroke. Ann Pharmacother. 2018;52(6):605-6. DOI:10.1177/1060028018759938.; Steinberg BA, Shrader P, Thomas L, et al.; ORBIT-AF Investigators and Patients. Off-Label Dosing of NonVitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. J Am Coll Cardiol. 2016;68(24):2597-604. DOI:10.1016/j.jacc.2016.09.966.; Ruiz Ortiz M, Muñiz J, RañaMíguez P, et al.; FANTASIIA study investigators. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace. 2018;20(10):1577-83. DOI:10.1093/europace/eux316.; Pattullo CS, Barras M, Tai B, et al. New oral anticoagulants: appropriateness of prescribing in real-world setting. Intern Med J. 2016;46(7):812-8. DOI:10.1111/imj.13118.; Okumura Y, Yokoyama K, Matsumoto N, et al.; The Sakura Af Registry Investigators. Current use of direct oral anticoagulants for atrial fibrillation in Japan: Findings from the SAKURA AF Registry. J Arrhythm. 2017;33(4):289-96. DOI:10.1016/j.joa.2016.11.003.; Yao X, Shah ND, Sangaralingham LR, et al. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol. 2017;69(23):2779-90. DOI:10.1016/j.jacc.2017.03.600.; Barnes GD, Nallamothu BK, Sales AE, Froehlich JB. Reimagining Anticoagulation Clinics in the Era of Direct Oral Anticoagulants. Circ Cardiovasc Qual Outcomes. 2016;9(2):182-5. DOI:10.1161/CIRCOUTCOMES. 115.002366.; Raval AN, Cigarroa JE, Chung MK, et al. Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. Circulation. 2017;135(10):e604-e633. DOI:10.1161/CIR.0000000000000477.; https://www.rpcardio.com/jour/article/view/2756

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2756
https://doi.org/10.20996/1819-6446-2022-05-02

Predictors of Thrombus Dissolution in the Left Atrial Appendage in Patients with Persistent Nonvalvular Atrial Fibrillation ; Предикторы растворения тромбов в ушке левого предсердия у больных персистирующей неклапанной фибрилляцией предсердий

Συγγραφείς: E. S. Mazur, V. V. Mazur, N. D. Bazhenov, Yu. A. Orlov, Е. С. Мазур, В. В. Мазур, Н. Д. Баженов, Ю. А. Орлов

Πηγή: The Russian Archives of Internal Medicine; Том 12, № 2 (2022); 129-135 ; Архивъ внутренней медицины; Том 12, № 2 (2022); 129-135 ; 2411-6564 ; 2226-6704

Θεματικοί όροι: пероральные антикоагулянты, transesophageal echocardiography, left atrial appendage thrombosis, oral anticoagulants, чреспищеводная эхокардиография, тромбоз ушка левого предсердия

Περιγραφή αρχείου: application/pdf

Relation: https://www.medarhive.ru/jour/article/view/1406/1104; https://www.medarhive.ru/jour/article/view/1406/1113; https://www.medarhive.ru/jour/article/downloadSuppFile/1406/795; Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю., и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021; 26(7): 4594. doi:10.15829/1560-4071-2021-4594.; Hindricks G., Potpara T., Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2020; 00: 1–125. doi:10.1093/eurheartj/ehaa612.; Lip G.Y.H., Hammerstingl C, Marin F. et al. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). American Heart Journal. 2016; 178: 126-34. doi:10.1016/j.ahj.2016.05.007.; Hussain A., Katz W.E., Genuardi M.V., et al. Non-vitamin K oral anticoagulants versus warfarin for left atrial appendage thrombus resolution in nonvalvular atrial fibrillation or flutter. Pacing Clin Electrophysiol. 2019; 42(9): 1183–1190. doi:10.1111/pace.13765.; Saeed M., Rahman A., Afzal A., et al. Role of transesophageal echocardiography guided cardioversion in patients with atrial fibrillatio, previous left atrial thrombus and effective anticoagulation. Int J Cardiol. 2006; 113(3): 401–405. doi:10.1016/j.ijcard.2006.03.036.; Mumoli N., Amellone C., Antonelli G., et al. Clinical discussions in antithrombotic therapy management in patients with atrial fibrillation: a delphi consensus panel. CJC Open. 2020; 2: 641–651. doi:10.1016/j.cjco.2020.07.016.; Hahn R.T., Abraham T., Adams M.S., et al. Guidelines for Performing a Comprehensive Transesophageal Echocardiographic Examination: Recommendations from the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists. J Am Soc Echocardiogr. 2013; 26: 921-64. doi:10.1016/j.echo.2013.07.009; Lattuca B., Bouziri N., Kerneis M. et al. Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus. J Am Coll Cardiol 2020; 75: 1676–85. doi:10.1016/j.jacc.2020.01.057; Oh J.K., Park J-H., Lee J-H., et al. Shape and Mobility of a Left Ventricular Thrombus Are Predictors of Thrombus Resolution. Korean Circ J. 2019; 49(9): 829-837. doi:10.4070/kcj.2018.0346.; Goldman М.Е., Pearce L.A., Hart R.G., et al. Pathophysiologic Correlates of Thromboembolism in Nonvalvular Atrial Fibrilla- tion: I. Reduced Flow Velocity in the Left Atrial Appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] Study). Journal of American Society of Echocardiography. 1999; 12: 1080–1087. doi:10.1016/s0894-7317(99)70105-7.; Lee J.M., Shim J., Uhm J.S., et al. Impact of Increased Orifice Size and Decreased Flow Velocity of Left Atrial Appendage on Stroke in Nonvalvular Atrial Fibrillation. American Journal of Cardiology. 2014; 113: 963-969. doi:10.1016/j. amjcard.2013.11.058.; Cresti A., Garcia-Fernandez M.A., De Sensi F., et al. Prevalence of auricular thrombosis before atrial flutter cardioversion: a 17-year transoesophageal echocardiographic study. Europace 2016; 18: 450–456. doi:10.1093/europace/euv128; Lee J.M., Kim J-B., Uhm J-S. et al. Additional value of left atrial appendage geometry and hemodynamics when considering anticoagulation strategy in patients with atrial fibrillation with low CHA2DS2-VASc scores. Heart Rhythm 2017; 14(1): 297– 1301. doi:10.1016/j.hrthm.2017.05.034; Голухова Е.З., Громова О.И., Аракелян М.Г. и др. Предикторы тромбоза ушка левого предсердия и тромбоэмболических осложнений у больных с фибрилляцией предсердий без сопутствующей клапанной патологии и ишемической болезни сердца. Креативная кардиология. 2017; 11(3): 262-72. doi:10.24022/1997-3187-2017-11-3-262-272.; Beigel R., Wunderlich N.C., Ho S.Y. et al. The Left Atrial Appendage: Anatomy, Function, and Noninvasive Evaluation. Journal of American College of Cardiology: Cardiovascular Imaging. 2014; 7(12): 1251-65. doi:10.1016/j.jcmg.2014.08.009.; Zateyshchikov D.A., Brovkin A.N., Chistiakov D.A., et al. Advanced age, low left atrial appendage velocity, and Factor V promoter sequence variation as predictors of left atrial thrombosis in patients with nonvalvular atrial fibrillation. Journal of Thrombosis and Thrombolysis. 2010; 30: 192-199. doi:10.1007/s11239-010-0440-1.; Niku A.D., Shiota T., Siegel R.J., et al. Prevalence and Resolution of Left Atrial Thrombus in Patients with Nonvalvular Atrial Fibrillationand Flutter with Oral Anticoagulation. Am. J. Cardiol. 2019; 123: 63–68. doi:10.1016/j.amjcard.2018.09.027; https://www.medarhive.ru/jour/article/view/1406

Διαθεσιμότητα: https://www.medarhive.ru/jour/article/view/1406
https://doi.org/10.20514/2226-6704-2021-12-2-129-135

Проблемы выбора антикоагулянта для вторичной профилактики инсульта у пациентов с фибрилляцией предсердий ; Problems of selecting an anticoagulant for secondary stroke prevention in patients with atrial fibrillation

Συγγραφείς: Gusev, V. V., Lvova, O. A., Shamalov, N. A., Гусев, В. В., Львова, О. А., Шамалов, Н. А.

Θεματικοί όροι: SCHEMIC STROKE, ATRIAL FIBRILLATION, SECONDARY PREVENTION, DIRECT ORAL ANTICOAGULANTS, ИШЕМИЧЕСКИЙ ИНСУЛЬТ, ФИБРИЛЛЯЦИЯ ПРЕДСЕРДИЙ, ВТОРИЧНАЯ ПРОФИЛАКТИКА, ПРЯМЫЕ ПЕРОРАЛЬНЫЕ АНТИКОАГУЛЯНТЫ

Περιγραφή αρχείου: application/pdf

Relation: Scopus; Гусев В.В., Львова О.А., Шамалов Н.А. Проблемы выбора антикоагулянта для вторичной профилактики инсульта у пациентов с фибрилляцией предсердий. Кардиоваскулярная терапия и профилактика. 2021;20(6):3044.; http://elib.usma.ru/handle/usma/7216

Διαθεσιμότητα: http://elib.usma.ru/handle/usma/7216

Efficiency of the Left Atrial Appendage Thrombus Dissolution in Patients with Persistent Nonvalvular Atrial Fibrillation with Warfarin or Direct Oral Anticoagulants Therapy ; Эффективность растворения тромбов в ушке левого предсердия у больных персистирующей неклапанной фибрилляцией предсердий при лечении варфарином и прямыми оральными антикоагулянтами

Συγγραφείς: E. Mazur S., V. Mazur V., N. Bazhenov D., Yu. Orlov A., Е. Мазур С., В. Мазур В., Н. Баженов Д., Ю. Орлов А.

Συνεισφορές: The study was performed with the support of the Tver State Medical University, Исследование проведено при поддержке Тверского государственного медицинского университета

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 17, No 5 (2021); 724-728 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 5 (2021); 724-728 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: atrial fibrillation, transesophageal echocardiography, left atrial appendage thrombosis, oral anticoagulants, warfarin, фибрилляция предсердий, чреспищеводная эхокардиография, тромбоз ушка левого предсердия, пероральные антикоагулянты, варфарин

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2583/2229; https://www.rpcardio.com/jour/article/view/2583/2244; Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю., и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. DOI:10.15829/1560-4071-2021-4594.; Hindricks G, Potpara T, Dagres N, et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2021;42(5):373-498. DOI:10.1093/eurheartj/ehaa612.; Lip GY, Hammerstingl C, Marin F, et al.; X-TRA study and CLOT-AF registry investigators. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2016;178:126-34. DOI:10.1016/j.ahj.2016.05.007.; Hussain A, Katz WE, Genuardi MV, et al. Non-vitamin K oral anticoagulants versus warfarin for left atrial appendage thrombus resolution in nonvalvular atrial fibrillation or flutter. Pacing Clin Electrophysiol. 2019;42(9):1183-90. DOI:10.1111/pace.13765.; Niku AD, Shiota T, Siegel RJ, Rader F. Prevalence and Resolution of Left Atrial Thrombus in Patients with Nonvalvular Atrial Fibrillationand Flutter with Oral Anticoagulation. Am J Cardiol. 2019;23(1):63-8. DOI:10.1016/j.amjcard.2018.09.027.; Ferner M, Wachtlin D, Konrad T, et al. Rationale and design of the RE-LATED AF-AFNET 7 trial: REsolution of Leftatrial-Appendage Thrombus-Effects of Dabigatran in patients with Atrial Fibrillation. Clin Res Cardiol. 2016;105(1):29-36. DOI:10.1007/s00392-015-0883-7.; Кропачева Е.С. Внутрисердечный тромбоз: частота, факторы риска и место пероральных антикоагулянтов в лечении. Атеротромбоз. 2020;(1):134-52. DOI:10.21518/2307-1109-2020-1-134-152.; Mumoli N, Amellone C, Antonelli G, et al. Clinical discussions in antithrombotic therapy management in patients with atrial fibrillation: a Delphi consensus panel. CJC Open 2020;2(6):641-51. DOI:10.1016/j.cjco.2020.07.016.; Xing FX, Liu NN, Han YL, et al. Anticoagulation efficacy of dabigatran etexilate for left atrial appendage thrombus in patients with atrial fibrillation by transthoracic and transesophageal echocardiography. Medicine (Baltimore). 2018;97(26):e11117. DOI:10.1097/MD.0000000000011117.; Harada M, Koshikawa M, Motoike Y, et al. Left Atrial Appendage Thrombus Prior to Atrial Fibrillation Ablation in the Era of Direct Oral Anticoagulants. Circ J. 2018;82(11):2715-21. DOI:10.1253/circj.CJ-18-0398.; Yilmaz KC, Ciftci O, Ozin B, Muderrisoglu H. Anticoagulants in left atrial thrombus resolution. Ann Med Res. 2020;27(7):1908-12. DOI:10.5455/annalsmedres.2020.03.284.; Фараг Ш.И., Арафа У.С., Хасан А.А.Э., и др. Реальная оценка профиля международного нормализованного отношения (МНО) у пациентов с неклапанной фибрилляцией предсердий, получающих антагонисты витамина K. Рациональная Фармакотерапия в Кардиологии. 2020;16(4):522-7. DOI:10.20996/1819-6446-2020-08-14.; Скирденко Ю.П., Николаев Н.А. Алгоритм выбора антикоагулянта для больных фибрилляцией предсердий. Рациональная Фармакотерапия в Кардиологии. 2020;16(2):199-205. DOI:10.20996/1819-6446-2020-04-16.; Lattuca B, Bouziri N., Kerneis M, et al. Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus. J Am Coll Cardiol. 2020;75(14):1676-85. DOI:10.1016/j.jacc.2020.01.057.; Oh JK, Park JH, Lee JH, et al. Shape and Mobility of a Left Ventricular Thrombus Are Predictors of Thrombus Resolution. Korean Circ J. 2019;49(9):829-37. DOI:10.4070/kcj.2018.0346.; https://www.rpcardio.com/jour/article/view/2583

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2583
https://doi.org/10.20996/1819-6446-2021-10-08

Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention ; Антитромботическая терапия у пациентов с фибрилляцией предсердий при чрескожных коронарных вмешательствах

Συγγραφείς: A. Panov V., А. Панов В.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 17, No 4 (2021); 628-637 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 4 (2021); 628-637 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: чрескожное коронарное вмешательство, фибрилляция предсердий, варфарин, прямые пероральные антикоагулянты, двойная и тройная антитромботическая терапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2546/2215; Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11(4):423-34. DOI:10.1093/europace/eun369.; Steinberg BA, Kim S, Piccini JP, et al. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2013;128(7):721-8. DOI:10.1161/CIRCULATIONAHA.113.002927.; Fox KAA, Velentgas P, Camm AJ, et al. Outcomes associated with oral anticoagulants plus antiplatelets in patients with newly diagnosed atrial fibrillation. JAMA Netw Open. 2020;3(2):e200107. DOI:10.1001/jamanetworkopen.2020.0107.; Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26(22):2422-34. DOI:10.1093/eurheartj/ehi505; Steffel1 Y, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021 Apr 25;euab065. DOI:10.1093/europace/euab065.; Depta JP, Cannon CP, Fonarow GC, et al. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol. 2009;104(9):1171-8. DOI:10.1016/j.amjcard.2009.06.027.; Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-17. DOI:10.1056/NEJMoa1107039.; Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903-12. DOI:10.1016/S01406736(06)68845-4.; Leon MB, Baim DS, Popma JJ, et al., Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998; 339(23):1665-71. DOI:10.1056/NEJM199812033392303.; Dentali F, Douketis JD, Lim W, et al. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med. 2007;167(2):117-24. DOI:10.1001/archinte.167.2.117.; Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433-41. DOI:10.1001/archinternmed.2010.271.; Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509-24. DOI:10.1056/NEJMoa1817083.; Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107-15. DOI:10.1016/S01406736(12)62177-1.; Gibson CM, Mehran R, Bode C, et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J. 2015;169(4):472-8.e5. DOI:10.1016/j.ahj.2014.12.006.; Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513-24. DOI:10.1056/NEJMoa1708454.; Vranckx P, Valgimigli M, Eckardt L, et al. Edoxabanbased versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients withatrial fibrillation (ENTRUSTAF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335-43. DOI:10.1056/NEJMoa1708454.; Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127(5):634-40. DOI:10.1161/CIRCULATIONAHA.112.115386.; Faxon DP, Eikelboom JW, Berger PB, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summa-ry. Circ Cardiovasc Interv. 2011;4(5):522-34. DOI:10.1161/CIRCINTERVENTIONS.111.965186.; Paikin JS, Wright DS, Crowther MA, et al. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation. 2010;121(18):2067-70. DOI:10.1161/CIRCULATIONAHA.109.924944.; Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2011;32(15):1854-64. DOI:10.1093/eurheartj/ehr204.; Fiedler K.A., Maeng M., Mehilli J., et al. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol. 2015;65(16):1619-29. DOI:10.1016/j.jacc.2015.02.050.; Фибрилляция и трепетание предсердий. Рекомендации Российского Кардиологического Общества (2020) [цитировано 30.06.2021. Доступно на: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_FP_TP.pdf.; Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российское кардиологическое общество, Ассоциация сердечно-сосудистых хирургов России. Российский Кардиологический Журнал. 2020;25(11):4103. DOI:10.15829/1560-4071-2020-4103.; Острый коронарный синдром без подъема сегмента ST электрокардиограммы. Рекомендации Российского Кардиологического Общества (2020). Российский Кардиологический Журнал. 2020;26(4):4449. DOI:10.15829/1560-4071-2021-4449.; Стабильная ишемическая болезнь сердца. Рекомендации Российского Кардиологического Общества (2020). Российский Кардиологический Журнал. 2020;25(11):201-51. DOI:10.15829/1560-4071-2020-4076.; Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. DOI:10.1093/eurheartj/ehaa612.; Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;77(5):629-58. DOI:10.1016/j.jacc.2020.09.011.; Lopes RD, Leonardi S, Wojdyla DM, et al. Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial. Circulation. 2019;141(9):781-3. DOI:10.1161/CIRCULATIONAHA.119.044584.; Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Circulation. 2018;138(5):527-36. DOI:10.1161/CIRCULATIONAHA.120.050438.; Lip GYH, Collet JP, Haude M, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the EHRA, EAPCI, ACCA endorsed by the HRS, APHRS, LAHRS, CASSA. Europace. 2019;21(2):192-3. DOI:10.1093/europace/euy174.; Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367(22):2100-9. DOI:10.1056/NEJMoa1209979.; Price MJ, Berger PB, Teirstein PS, et al. Standardvs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097-105. DOI:10.1001/jama.2011.290.; Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol. 2012;59(24):2159-64. DOI:10.1016/j.jacc.2012.02.026.; Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381(17):1621-31. DOI:10.1056/NEJMoa1907096.; Yasuda S, Kaikita K, Akao M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381():1103-13. DOI:10.1056/NEJMoa1904143.; Matsumura-Nakano Y, Shizuta S, Komasa A, et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. Circulation. 2019;139(5):604-16. DOI:10.1161/CIRCULATIONAHA.118.036768.; Berry NC, Mauri L, Steg PG, et al. Effect of lesion complexity and clinical risk factors on the efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: a subgroup analysis from the REDUAL PCI trial. Circ Cardiovasc Interv. 2020;13(4):e008349. DOI:10.1161/CIRCINTERVENTIONS.119.008349.; Rossini R, Musumeci G, Lettieri C, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol. 2008;102(12):1618-23. DOI:10.1016/j.amjcard.2008.08.021.; Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebocontrolled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74. DOI:10.1038/clpt.2010.219.; Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937-44. DOI:10.1001/jama.2009.261.; Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909-17. DOI:10.1056/NEJMoa1007964.; Tada T, Byrne RA, Simunovic I, et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents,and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv. 2013;6(12):1267-74. DOI:10.1016/j.jcin.2013.06.015.; Rubboli A, Lip GYH. Algorithm for the management of antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention: an updated proposal based on efficacy considerations. Eur Heart J Cardiovasc Pharmacother. 2020;6(3):197-8. DOI:10.1093/ehjcvp/pvaa003.; Baker NC, O’Connell EW, Htun WW, et al. Safety of coronary angiography andpercutaneous coronary intervention via the radial versus femoral route inpatients on uninterrupted oral anticoagulation with warfarin. Am Heart J. 2014;168(4):537-44. DOI:10.1016/j.ahj.2014.06.016.; Chongprasertpon N, Zebrauskaite A, Coughlan JJ, et al. Performing diagnostic radial access coronary angiog-raphy on uninterrupted direct oral anticoagulant therapy: a prospective analysis. Open Heart. 2019;6(1):e0010. DOI:10.1136/openhrt-2019-001079.; Giustino G, Chieffo A, Palmerini T et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol. 2016;68(17):1851-64. DOI:10.1016/j.jacc.2016.07.760.; Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC Scientific Document Group. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. DOI:10.1093/eurheartj/ehy394.; Knuuti J, Wijns W, Saraste A, Capodanno D, et al. ESC Scientific Document Group. 2019 ESC guidelines for the diagnosis a management of chronic coronary syndromes. Eur Heart J. 2020;41(3):40777. DOI:10.1093/eurheartj/ehz425; Wallentin L, Becker RC, Budaj A, et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57. DOI:10.1056/NEJMoa0904327.; Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15. DOI:10.1056/NEJMoa0706482.; Jackson LR, Ju C, Zettler M, Messenger JC, et al. Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS study. ACC Cardiovasc Interv. 2015;8(14):1880-9. DOI:10.1016/j.jcin.2015.08.018.; Valgimigli M, Bueno H, Byrne RA, et al. ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the ESC and of the EACTS. Eur Heart J. 2018;39(3):213-60. DOI:10.1093/eurheartj/ehx419.; Lau WCY, Douglas IJ, Wong ICK, et al. Thromboembolic, bleeding, and mortalityrisks among patients with nonvalvular atrial fibrillation treated with dual antiplatelet therapy versus oral anticoagulants: a population-based study. Heart Rhythm. 2020;17(1):33-40. DOI:10.1016/j.hrthm.2019.07.034.; Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin inpatients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62. DOI:10.1016/S0140-6736(13)62343-0.; Genereux P, Giustino G, Witzenbichler B, et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol. 2015;66(9):1036-45. DOI:10.1016/j.jacc.2015.06.1323.; ten Berg JM, de Veer A, Oldgren J, Steg PG, et al. RE-DUAL PCI Steering Committee and Investigators. Switching of oral anticoagulation therapy after PCI in patients with atrial fibrillation: the RE-DUAL PCI trial subanalysis. JACC Cardiovasc Interv. 2019;12(23):2331-41. DOI:10.1016/j.jcin.2019.08.039.; Rubboli A, Valgimigli M, Capodanno D, et al. Choices in antithrombotic management for patients with atrial fibrillation undergoing percutaneous coronary intervention: questions (and answers) in chronological sequence. Eur Heart J – Cardiovascular Pharmacotherapy. 2021;7(1):68-73. DOI:10.1093/ehjcvp/pvaa047.; Rubboli A, Lisi M. After the AUGUSTUS trial, should apixaban be the only directoral anticoagulant to be used in triple therapy in atrial fibrillation patients under-going percutaneous coronary intervention? Cardiovasc Drugs Ther. 2019;33(4):499-500. DOI:10.1007/s10557-019-06886-w.; Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e326S-e350S. DOI:10.1378/chest.11-2298.; Eikelboom JW, Connolly S J, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377(14):1319-1330. DOI:10.1056/NEJMoa1709118.; Mega J, Braunwald E, Wiviott S, et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med. 2012;366(1):9-19. DOI:10.1056/NEJMoa1112277.; Pradaxa. Summary of product characteristics. European Medicines Agency DSoPC [cited by Jun 30, 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/pradaxa-epar-product-information_en.pdf.; van Es RF, Jonker JJ, Verheugt FW, et al. Antithrombotics in the Secondary Prevention of Events in CoronaryThrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002;360(9327):109-13. DOI:10.1016/S0140-6736(02)09409-6.; Hurlen M, Abdelnoor M, Smith P et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347(13):969-74. DOI:10.1056/NEJMoa020496.; Hamon M, Lemesle G, Tricot O, et al. Incidence, source, determinants, and prognostic im-pact of major bleeding in outpatients with stable coronary artery disease. J Am Coll Cardiol. 2014;64(14):1430-6. DOI:10.1016/j.jacc.2014.07.957.; Yasuda S, Kaikita K, Akao M, et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med. 2019;381(12):1103-13. DOI:10.1056/NEJMoa1904143.; https://www.rpcardio.com/jour/article/view/2546

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2546
https://doi.org/10.20996/1819-6446-2021-07-02

Approaches to Assessing the Quality of Observational Studies of Clinical Practice Based on the Big Data Analysis ; Подходы к оценке качества наблюдательных исследований клинической практики, основанных на анализе «больших данных»

Συγγραφείς: S. Gilyarevsky R., С. Гиляревский Р.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 17, No 4 (2021); 584-593 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 4 (2021); 584-593 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: clinical practice studies, big data, pharmacoepidemiological studies, direct oral anticoagulants, исследования реальной клинической практики, «большие данные», фармакоэпидемиологические исследования, прямые пероральные антикоагулянты

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2541/2210; U.S. Food and Drug Administration. Framework for FDA’s realworld evidence programa (2018) [cited by Jun 30, 2021. Available from: https://www.fda.gov/media/120060/download.; Berger ML, Doban V. Big data, advanced analytics and the future of comparative effectiveness research. J Comp Eff Res. 2014;3(2):167-76. DOI:10.2217/cer.14.2.; Okada M. Big data and real-world data-based medicine in the management of hypertension. Hypertens Res. 2021;44(2):147-53. DOI:10.1038/s41440-020-00580-3.; Hay SI, George DB, Moyes CL, Brownstein JS. Big data opportunities for global infectious disease surveillance. PLoS Med. 2013;10(4):e1001413. DOI:10.1371/journal.pmed.1001413.; Ola O, Sedig K. The challenge of big data in public health: an opportunity for visual analytics. Online J Public Health Inform. 2014;5(3):223. DOI:10.5210/ojphi.v5i3.4933.; Fanaroff AC, Califf RM, Lopes RD. New Approaches to Conducting Randomized Controlled Trials. J Am Coll Cardiol 2020;75:556-9. DOI:10.1016/j.jacc.2019.11.043.; Murray KW, Duggan A. Understanding Confounding in Research Pediatr Rev. 2010;31(3):124-6. DOI:10.1542/pir.31-3-124.; Meuli L, Dick F. Understanding Confounding in Observational Studies. Eur J Vasc Endovasc Surg. 2018;55(5):737. DOI:10.1016/j.ejvs.2018.02.028.; Fanaroff AC, Califf RM, Windecker S, et al. Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018. JAMA. 2019;321:1069-80. DOI:10.1001/jama.2019.1122.; Гиляревский С.Р., Гаврилов Д.В., Гусев А.В. Результаты ретроспективного анализа записей электронных амбулаторных медицинских карт пациентов с хронической сердечной недостаточностью: первый российский опыт. Российский Кардиологический Журнал. 2021;26(5):4502. DOI:10.15829/1560-4071-2021-4502.; Althubaiti A. Information bias in health research: definition, pitfalls, and adjustment methods. J Multidiscip Healthc. 2016;9:211-7. DOI:10.2147/JMDH.S104807.; Matsumoto S, Fukui M, Hamaguchi M, et al. Is home blood pressure reporting in patients with type 2 diabetes reliable? Hypertens Res. 2014;37(8):741-5. DOI:10.1038/hr.2014.66.; Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512-22. DOI:10.1097/EDE.0b013e3181a663cc.; Cox DR, Kartsonaki C, Keogh RH. Big data: Some statistical issues. Stat Probab Lett. 2018;136:1115. DOI:10.1016/j.spl.2018.02.015.; Beaulieu-Jones BK, Finlayson SG, Yuan W, et al. Examining the Use of Real-World Evidence in the Regulatory Process. Clin Pharmacol Ther. 2020;107(4):843-52. DOI:10.1002/cpt.1658.; Langan SM, Schmidt SA, Wing K, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ. 2018;363:k3532. DOI:10.1136/bmj.k3532.; Benchimol EI, Smeeth L, Guttmann A, et al.; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 2015;12(10):e1001885. DOI:10.1371/journal.pmed.1001885.; von Elm E, Altman DG, Egger M, et al.; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-7. DOI:10.1016/S0140-6736(07)61602-X.; Hemkens LG, Benchimol EI, Langan SM, et al. The reporting of studies using routinely collected health data was often insufficient. J Clin Epidemiol. 2016;79:104-11. DOI:10.1016/j.jclinepi.2016.06.005.; Dreyer NA, Schneeweiss S, McNeil BJ, et al.; GRACE Initiative. GRACE principles: recognizing highquality observational studies of comparative effectiveness. Am J Manag Care. 2010;16(6):467-71.; European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on methodological standards in pharmacoepidemiology (2011) [cited by Jun 30, 2021. Available from: www.encepp.eu/standards_and_guidances/methodologicalGuide.shtml.; Blake KV, Devries CS, Arlett P, et al.; for the European Network of Centres for Pharmacoepidemiology Pharmacovigilance. Increasing scientific standards, independence and transparency in post-authorisation studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Pharmacoepidemiol Drug Saf. 2012;21(7):690-6. DOI:10.1002/pds.3281.; Franklin JM, Schneeweiss S. When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials? Clin Pharmacol Ther. 2017;102(6):924-33. DOI:10.1002/cpt.857.; Schneeweiss S. Improving therapeutic effectiveness and safety through big healthcare data. Clin Pharmacol Ther. 2016;99(3):262-5. DOI:10.1002/cpt.316; Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-World Evidence What Is It and What Can It Tell Us? N Engl J Med. 2016;375(23):2293-7. DOI:10.1056/NEJMsb1609216.; Guimarães PO, Krishnamoorthy A, Kaltenbach LA, et al. Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction: A Secondary Analysis of the TRANSLATE-ACS Study. JAMA Cardiol. 2017;2(7):750-7. DOI:10.1001/jamacardio.2017.1460.; Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. In: The Cochrane Collaboration, ed. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2014 [cited by Jun 30, 2021. Available from: http://doi.wiley.com/10.1002/14651858.MR000034.pub2. Accessed May 12, 2016.; Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JPA. Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey. BMJ. 2016;352:i493. DOI:10.1136/bmj.i493.; Dahabreh IJ, Sheldrick RC, Paulus JK, et al. Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes. Eur Heart J. 2012;33(15):1893-901. DOI:10.1093/eurheartj/ehs114.; Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med. 1991;325(11):756-62. DOI:10.1056/NEJM199109123251102.; Rossouw JE, Anderson GL, Prentice RL, et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):32133. DOI:10.1001/jama.288.3.321.; Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. a prospective, observational study. Ann Intern Med. 2001;135(1):1-8. DOI:10.7326/0003-4819-135-1-200107030-00003.; Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19(6):766-79. DOI:10.1097/EDE.0b013e3181875e61.; Goodman SN, Schneeweiss S, Baiocchi M. Using Design Thinking to Differentiate Useful From Misleading Evidence in Observational Research. JAMA. 2017;317(7):705-7. DOI:10.1001/jama.2016.19970.; Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med. 2008;358(8):771-83. DOI:10.1056/NEJMoa0707571.; Fergusson DA, Hébert PC, Mazer CD, et al.; BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358(22):2319-31. DOI:10.1056/NEJMoa0802395.; Agoritsas T, Merglen A, Shah ND, et al. Adjusted Analyses in Studies Addressing Therapy and Harm: Users' Guides to the Medical Literature. JAMA. 2017;317(7):748-59. DOI:10.1001/jama.2016.20029.; ISPOR Membership profile [cited by May 12, 2021. Available from: URL: https://www.ispor.org.; Proietti M, Romanazzi I, Romiti GF, et al. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. Stroke. 2018;49(1):98-106. DOI:10.1161/STROKEAHA.117.018395.; Escobar C, MartÍ-Almor J, Pérez Cabeza A, MartÍnez-Zapata MJ. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis. Rev Esp Cardiol (Engl Ed). 2019;72(4):305-16. DOI:10.1016/j.rec.2018.03.009.; https://www.rpcardio.com/jour/article/view/2541

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2541
https://doi.org/10.20996/1819-6446-2021-08-01

Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis ; ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ НОВЫХ ПЕРОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ У БОЛЬНЫХ С ВЕНОЗНЫМИ ТРОМБОЭМБОЛИЧЕСКИМИ ОСЛОЖНЕНИЯМИ: МЕТА-АНАЛИЗ

Συγγραφείς: V. Petrov I., O. Shatalova V., V. Gorbatenko S., O. Smuseva N., A. Maslakov S., В. Петров И., О. Шаталова В., В. Горбатенко С., О. Смусева Н., А. Маслаков С.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 12, No 6 (2016); 31-39 ; Рациональная Фармакотерапия в Кардиологии; Vol 12, No 6 (2016); 31-39 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2016-12-6

Θεματικοί όροι: randomized clinical trials, meta-analysis, new oral anticoagulants, venous thromboembolism, рандомизированные контролируемые исследования, мета-анализ, новые пероральные антикоагулянты, венозные тромбоэмболические осложнения

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/1192/1220; Savelyev VS, Chazov EI, Gusev EI, et al. The Russian clinical recommendations for diagnosis, treatment and prevention of venous thromboembolic events. Flebologiia 2010; 4: 1-40. In Russian (Савельев В.С., Чазов Е.И. Гусев Е.И. и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология 2010; 4: 1-40).; Heit J., Cohen A., Anderson F. et al. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood (ASH Annual Meeting Abstracts) 2005; 106: Abstract 910.; Cohen A., Agnelli G., Anderson F. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-64.; Spencer F., Emery C., Lessard D. et al. The Worcester Venous Thromboembolism study: a populationbased study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 722-7.; Cohen A., Dobromirski M. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism. Thromb Haemost 2012; 107 (6): 1035-43.; Guidelines on the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology, 2014; Kearon C., Akl E., Comerota A. et al. Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl 2): S419-94.; Ansell J., Hirsh J., Hylek E. et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest 2008; 133: S160-98.; Moher D., Liberati A., Tetzlaff J., Altman D.G. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med 2009; 3: 123-30.; Lau J., Ioannidis J.P., Schmid C.H. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820-6.; Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48.; DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.; Higgins J.P., Thompson S.G. Quantifying heterogeneity in a metaanalysis. Stat Med 2002; 21: 1539- 58.; The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.; The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97.; Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.; Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014;129:764-72.; Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (9): 799-808.; Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal 2013; 11:21.; https://www.rpcardio.com/jour/article/view/1192

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/1192

Regarding the management of an elderly patient with atrial fibrillation

Πηγή: Лекарства Украины; № 8(254) (2021); 20-26
Medicine of Ukraine; No. 8(254) (2021); 20-26
Ліки України; № 8(254) (2021); 20-26

Θεματικοί όροι: screening, пероральні антикоагулянти, фібриляція передсердь, антидоты, 3. Good health, фибрилляция предсердий, профилактика, prevention, профілактика, скринінг, atrial fibrillation, антидоти, oral anticoagulants, antidotes, скрининг, пероральные антикоагулянты

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: http://lu-journal.com.ua/article/view/245797

Main indications for peroral anticoagulants: how to choose an optimal drug

Συγγραφείς: I. S. Yavelov

Πηγή: Качественная клиническая практика, Vol 0, Iss 3, Pp 53-60 (2018)

Θεματικοί όροι: пероральные антикоагулянты, апиксабан, дабигатрана этексилат, ривароксабан, варфарин, peroral anticoagulants, apixaban, dabigatran, rivaroxaban, warfarin, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441

Περιγραφή αρχείου: electronic resource

Relation: https://www.clinvest.ru/jour/article/view/95; https://doaj.org/toc/2588-0519; https://doaj.org/toc/2618-8473

Σύνδεσμος πρόσβασης: https://doaj.org/article/292b3c579acb4960800c3de15b479268

The Oral Anticoagulants Administration in Elderly Patients with Geriatric Syndromes: What's New? ; Применение пероральных антикоагулянтов у пожилых пациентов с гериатрическими синдромами: что нового?

Συγγραφείς: N. Vorobyeva M., O. Tkacheva N., Н. Воробьева М., О. Ткачева Н.

Συνεισφορές: The article was published with the financial support of the Pfizer company., Статья опубликована при финансовой поддержке компании Пфайзер.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 16, No 6 (2020); 984-993 ; Рациональная Фармакотерапия в Кардиологии; Vol 16, No 6 (2020); 984-993 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: elderly patient, geriatric syndrome, oral anticoagulants, atrial fibrillation, senile asthenia, venous thromboembolic complications, пожилой пациент, гериатрический синдром, пероральные антикоагулянты, фибрилляция предсердий, старческая астения, венозные тромбоэмболические осложнения

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2359/2097; Beard J.R., Officer A., de Carvalho I.A., et al. The World report on ageing and health: a policy framework for healthy ageing. Lancet. 2016;387(10033):2145-54. DOI:10.1016/S0140-6736(15)00516-4.; Shah S.J., Fang M.C., Jeon S.Y., et al. Geriatric Syndromes and Atrial Fibrillation: Prevalence and Association with Anticoagulant Use in a National Cohort of Older Americans. J Am Geriatr Soc. 2020. DOI:10.1111/jgs.16822.; Hindricks G., Potpara T., Dagres N., et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2020;00:1-126. DOI:10.1093/eurheartj/ehaa612.; Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. DOI:10.1056/NEJMoa0905561.; Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. DOI:10.1056/NEJMoa1009638.; Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. DOI:10.1056/NEJMoa1107039.; Giugliano R.P., Ruff C.T., Braunwald E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104. DOI:10.1056/NEJMoa1310907.; Grymonprez M., Steurbaut S., De Backer T.L., et al. Effectiveness and Safety of Oral Anticoagulants in Older Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Front Pharmacol. 2020;11:583311. DOI:10.3389/fphar.2020.583311.; Deitelzweig S., Keshishian A., Li X., et al. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients. J Am Geriatrics Soc. 2019;67(8):1662-71. DOI:10.1111/jgs.15956.; Kim H.M., Choi E.K., Park C.S., et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation. PloS One. 2019;14(3):e0211766. DOI:10.1371/journal.pone.0211766.; Russo V., Attena E., Di Maio M., et al. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study. J Thromb Thrombolysis. 2019;49(1):42-53. DOI:10.1007/s11239-019-01923-9.; Shinohara M., Wada R., Yao S., et al. Evaluation of oral anticoagulants in atrial fibrillation patients over 80 years of age with nonsevere frailty. J Arrhythmia. 2019;35(6):795-803. DOI:10.1002/joa3.12231.; Lai C.L., Chen H.M., Liao M.T., Lin T.T. Dabigatran, Rivaroxaban, and Warfarin in the Oldest Adults with Atrial Fibrillation in Taiwan. J Am Geriatrics Soc. 2018;66(8):1567-74. DOI:10.1111/jgs.15430.; Poli D., Antonucci E., Ageno W., et al. Oral anticoagulation in very elderly patients with atrial fibrillation: Results from the prospective multicenter START2-REGISTER study. PloS One. 2019;14(5):e0216831. DOI:10.1371/journal.pone.0216831.; Giustozzi M., Vedovati M.C., Verso M., et al. Patients aged 90years or older with atrial fibrillation treated with oral anticoagulants: A multicentre observational study. Int J Cardiol. 2019;281:56-61. DOI:10.1016/j.ijcard.2019.01.071.; Kwon S., Lee S.R., Choi E.K., et al. Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: A nationwide population-based study. Am Heart J. 2020;229:81-91. DOI:10.1016/j.ahj.2020.08.006.; Raposeiras-Roubin S., Alonso Rodriguez D., Camacho Freire S.J., et al. Vitamin K Antagonists and Direct Oral Anticoagulants in Nonagenarian Patients With Atrial Fibrillation. J Am Med Directors Assoc. 2020;21(3):367-373.e1. DOI:10.1016/j.jamda.2019.08.033.; Shah S.J., Singer D.E., Fang M.C., et al. Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation. Circ Cardiovasc Qual Outcomes. 2019;12(11):e006212. DOI:10.1161/CIRCOUTCOMES.119.006212.; Alexander K.P., Brouwer M.A., Mulder H., et al. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. Am Heart J. 2019;208:123-31. DOI:10.1016/j.ahj.2018.09.017.; Jaspers Focks J., Brouwer M.A., Wojdyla D.M., et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016;353:i2868. DOI:10.1136/bmj.i2868.; Piccini J.P., Hellkamp A.S., Washam J.B., et al. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Circulation. 2016;133(4):352-60. DOI:10.1161/CIRCULATIONAHA.115.018544.; Harskamp R.E., Teichert M., Lucassen W.A.M., et al. Impact of Polypharmacy and P-Glycoprotein-and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation. Cardiovasc Drugs Ther. 2019;33(5):615-23. DOI:10.1007/s10557-019-06907-8.; Kim I.S., Kim H.J., Yu H.T., et al. Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis. J Cardiol. 2019;73(6):515-21. DOI:10.1016/j.jjcc.2018.12.018.; Man-Son-Hing M., Nichol G., Lau A., et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159:677-85. DOI:10.1001/archinte.159.7.677.; Rao M.P., Vinereanu D., Wojdyla D.M., et al. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. Am J Med. 2018;131:269-75.e2. DOI:10.1016/j.amjmed.2017.10.036.; Steffel J., Giugliano R.P., Braunwald E., et al. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. J Am CollCardiol. 2016;68(11):1169-78. DOI:10.1016/j.jacc.2016.06.034.; Ткачева О.Н., Котовская Ю.В., Рунихина Н.К., и др. Старческая астения. Клинические рекомендации. Российский Журнал Гериатрической Медицины. 2020;1:11-46. DOI:10.37586/2686-8636-1-2020-11-46.; Kim S., Yoon S., Choi J., et al. Clinical implication of frailty assessment in older patients with atrial fibrillation. Arch GerontolGeriatr. 2017;70:1-7. DOI:10.1016/j.archger.2016.12.001.; Perera V., Bajorek B.V., Matthews S., et al. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing. 2009;38:156-62. DOI:10.1093/ageing/afn293.; Nguyen T. N., Morel-Kopp M. C., Pepperell D. et al. The impact of frailty on coagulation and responses to warfarin in acute older hospitalised patients with atrial fibrillation: A pilot study. Aging Clin Exp Res. 2017;29:1129-38. DOI:10.1007/s40520-017-0733-8.; Lip G.Y.H., Banerjee A., Boriani G., et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154:1121-201. DOI:10.1016/j.chest.2018.07.040.; Induruwa I., Evans N.R., Aziz A., et al. Clinical frailty is independently associated with non-prescription of anticoagulants in older patients with atrial fibrillation. Geriatr Gerontol Int. 2017;17(11):2178-83. DOI:10.1111/ggi.13058.; Ткачева О.Н., Котовская Ю.В., Рунихина Н.К., и др. Клинические рекомендации «Старческая астения». Часть 2. Российский Журнал Гериатрической Медицины. 2020;2:115-30. DOI:10.37586/2686-8636-2-2020-115-130.; Martinez B.K., Sood N.A., Bunz T.J., Coleman C.I. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2018;7:e008643. DOI:10.1161/JAHA.118.008643.; Lip G.Y.H., Keshishian A.V., Kang A.L., et al. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. J Intern Med. 2020. DOI:10.1111/joim.13140.; Prins M.H., Lensing A.W., Bauersachs R., et al., EINSTEIN Investigators: Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11:21. DOI:10.1186/1477-9560-11-21.; Buller H.R., Decousus H., Grosso M.A., et al.; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-15. DOI:10.1056/NEJMoa1306638.; Trujillo-Santos J., Beroiz P., Moustafa F., et al.; RIETE Investigators. Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism. Thromb Res. 2020;193:160-5. DOI:10. 1016/j.thromres.2020.06.035.; Orkaby A.R., Ozonoff A., Reisman J.I., et al. Continued Use of Warfarin in Veterans with Atrial Fibrillation After Dementia Diagnosis. J Am Geriatrics Soc. 2017;65(2):249-56. DOI:10.1111/jgs.14573.; Subic A., Cermakova P., Religa D., et al. Treatment of Atrial Fibrillation in Patients with Dementia: A Cohort Study from the Swedish Dementia Registry. J Alzheimers Dis. 2018;61(3):1119-28. DOI:10.3233/JAD-170575.; Fanning L., Lau W.C.Y., Mongkhon P., et al. Safety and Effectiveness of Direct Oral Anticoagulants vs Warfarin in People With Atrial Fibrillation and Dementia. J Am Med Directors Assoc. 2020;21(8):1058-64.e6. DOI:10.1016/j.jamda.2019.11.022.; Wehling M. Drug therapy in the elderly: too much or too little, what to do? A new assessment system: fit for the aged (FORTA) [in German]. Dtsch Med Wochenschr. 2008;133:2289-91. DOI:10.1055/s-0028-1091275.; Wehling M. Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: fit for the aged. J Am Geriatr Soc. 2009;57:560-61. DOI:10.1111/j.1532-5415.2009.02131.x.; Kuhn-Thiel A.M., Weiss C., Wehling M. Consensus validation of the FORTA (Fit fOR The Aged) List: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging. 2014;31:131-40. DOI:10.1007/s40266-013-0146-0.; Pazan F., Weiss C., Wehling M. The FORTA (Fit fOR The Aged) list 2018: third version of a validated clinical tool for improved drug treatment in older people. Drugs Aging. 2019;36:481-4. DOI:10.1007/s40266-019-00669-6.; Michalek C., Wehling M., Schlitzer J., Frohnhofen H. Effects of «Fit fOR The Aged» (FORTA) on pharmacotherapy and clinical endpoints — a pilot randomized controlled study. Eur J Clin Pharmacol. 2014;70:1261-7. DOI:10.1007/s00228-014-1731-9.; Wehling M., Burkhardt H., Kuhn-Thiel A.M., et al. VALFORTA - a randomized trial to validate the FORTA («Fit fOR The Aged») classification. Age Ageing. 2016;45:262-7. DOI:10.1093/ageing/afv200.; Pazan F., Burkhardt H., Frohnhofen H., et al. Changes in prescription patterns in older hospitalized patients: the impact of FORTA on disease-related over- and under-treatments. Eur J Clin Pharmacol. 2018;74:339-47. DOI:10.1007/s00228-017-2383-3.; Wehling M., Collins R., Gil V.M., et al. Appropriateness of oral anticoagulants for the long-term treatment of atrial fibrillation in older people. Results of an Evidence-Based Review and International Consensus Validation Process (OAC-FORTA 2016). Drugs Aging. 2017;34(7):499-507. DOI:10.1007/s40266-017-0466-6.; Воробьева Н.М., Ткачева О.Н. Антикоагулянтная терапия у пожилых пациентов: дилемма выбора между эффективностью и безопасностью. Медицинский Алфавит. 2018;2(16):6-14.; Воробьева Н. М., Ткачева О. Н. Пожилой пациент с фибрилляцией предсердий: как повысить безопасность антикоагулянтной терапии? Доктор.Ру. 2019;10(165):16-22. DOI:10.31550/1727-2378-2019-165-10-16-22.; Pazan F., Collins R., Gil V.M., et al. A Structured Literature Review and International Consensus Validation of FORTA Labels of Oral Anticoagulants for Long-Term Treatment of Atrial Fibrillation in Older Patients (OAC-FORTA 2019). Drugs Aging. 2020;37:539-48. DOI:10.1007/s40266-020-00771-0.; https://www.rpcardio.com/jour/article/view/2359

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2359
https://doi.org/10.20996/1819-6446-2020-12-03

Off-Label Medicines Use: Complex Problem of Modern Clinical Practice ; Назначение лекарственных препаратов по показаниям, не указанным в инструкции («off-label»): сложная проблема современной клинической практики

Συγγραφείς: S. Gilyarevskiy R., С. Гиляревский Р.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 16, No 2 (2020); 324-334 ; Рациональная Фармакотерапия в Кардиологии; Vol 16, No 2 (2020); 324-334 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: off-label use, on-label use, direct oral anticoagulants, ivabradine, apixaban, rivaroxaban, назначения off-label, назначения on-label, прямые пероральные антикоагулянты, ивабрадин, апиксабан, ривароксабан

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2181/1974; Приказ Минздрава России (Министерство здравоохранения РФ) от 14 января 2019 г. №4н «Об утверждении порядка назначения лекарственных препаратов, форм рецептурных бланков на лекарственные препараты, порядка оформления указанных бланков, их учета и хранения» Опубликован на официальном интернет-портале правовой информации 27.03.19 г. [цитировано 01.04.2020. Доступно на: https://rg.ru/2019/03/29/minzdrav-prikaz4-site-dok.html.; Kalil A.C. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA. 2020 Mar 24. DOI:10.1001/jama.2020.4742. [Epub ahead of print].; Chen Z., Hu J., Zhang Z., et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. [cited by April 01, 2020]. Available from: https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v3. DOI:10.1101/2020.03.22.20040758.; European Medicines Agency, Guideline on good pharmacovigilance practices, Module VI - Management and reporting of adverse reactions to medicinal products. [cited by April 01, 2020]. Available from: www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilancepractices-module-vi-management-reporting-adverse-reactions_en-0.pdf , para VI.A.2.1.2.; Bauman N.L., Sandefur C. Restoring Free Speech in Medicine: How state lawmakers can overcome FDA regulations that keep doctors and payers in the dark. Goldwater Institute, at 3, June 6, 2017 [cited by April 01, 2020]. Available from: https://ssrn.com/abstract=2982168.; O’Reilly J., Dalal A. Off label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs. Ann Health Law. 2003;12(2):295-324.; Mello M., Studdert D.M., Brennan T.A. Shifting terrain in the regulation of off-label promotion of pharmaceuticals. N Engl J Med. 2009;360(15):1557-66. DOI:10.1056/NEJMhle0807695.; Code of Federal Regulations. 21CFR312.2. Investigational new drug application [cited by April 01, 2020]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.2.; Ventola C.L. Off-label drug information: regulation, distribution, evaluation, and related controversies. P T. 2009;34(8):428-40.; Mithani Z. Informed consent for off-label use of prescription medications. Virtual Mentor. 2012;14(7):576-81. DOI:10.1001/virtualmentor.2012.14.7.oped1-1207.; Meadows W.A., Hollowell B.D. “Off-label” drug use: an FDA regulatory term, not a negative implication of its medical use. Int J Impot Res. 2008;20(2):135-44. DOI:10.1038/sj.ijir.3901619.; Fitzgerald A.S., O’Malley P.G. Staying on track when prescribing off-label. Am Fam Physician. 2014;89:4-5.; Wittich C.M., Burkle C.M., Lanier W.L. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc. 2012;87(10):982-90. DOI:10.1016/j.mayocp.2012.04.017.; Gazarian M., Kelly M., McPhee J.R., et al. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust. 2006;185(10):544-8. DOI:10.5694/j.1326-5377.2006.tb00689.; Radley D.C., Finkelstein S.N., Stafford R.S. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021-6. DOI:10.1001/archinte.166.9.1021.; Shah S.S., Hall M., Goodman D.M., et al. Off-label Drug Use in Hospitalized Children. Arch Pediatr Adolesc Med. 2007;161(3):282-90. DOI:10.1001/archpedi.161.3.282.; Qureshi Z.P., Liu Y., Sartor O., et al. Enforcement actions involving Medicaid fraud and abuse, 1996- 2009. Arch Intern Med. 2011;171(8):785-7. DOI:10.1001/archinternmed.2011.142.; Chen H., Reeves J.H., Fincham J.E., et al. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia Medicaid enrollees in 2001. J Clin Psychiatry. 2006;67:972- 82. DOI:10.4088/jcp.v67n0615.; Lat I., Micek S., Janzen J., et al. Off-label medication use in adult critical care patients. J Crit Care. 2011;26:89-94. DOI:10.1016/j.jcrc.2010.06.012.; Lin H.W., Phan K., Lin S.J. Trends in off-label beta-blocker use: a secondary data analysis. Clin Ther. 2006;28(10):1736-46. DOI:10.1016/j.clinthera.2006.10.015.; Loder E.W., Biondi D.M. Off-label prescribing of drugs in specialty headache practice. Headache. 2004;44:636-41. DOI:10.1111/j.1526-4610.2004.04121.x.; Picard D., Carvalho P., Bonnavia C., et al. Evaluation des prescriptions hors AMM en Dermatologie [Assessment off-label prescribing in dermatology]. Ann Dermatol Venereol. 2003;130: 507-10. DOI:AD-05-2003-130-5-0151-9638-101019-ART3.; Ratner M. Pfizer settles largest ever fraud suit for off-label promotion. Nat Biotechnol. 2009;27(11):961-2. DOI:10.1038/nbt1109-961.; Kmietowicz Z. Eli Lilly pays record $1.4bn for promoting off-label use of olanzapine. BMJ. 2009;338:b217. DOI:10.1136/bmj.b217.; Weda M., Hoebert J., Vervloet M., et al. Study on off-label use of medicinal products in the European (2019) [cited by April 01, 2020]. Available from: https://op.europa.eu/en/publication-detail/-/publication/ecf85518-d376-11e9-b4bf-01aa75ed71a110.2875/464022.; Schrier L., Hadjipanayis A., Stiris T., et al. Off-label use of medicines in neonates, infants, children, and adolescents: a joint policy statement by the European Academy of Paediatrics and the European society for Developmental Perinatal and Pediatric Pharmacology. Eur J Pediatr. 2020;179(5):839- 847. DOI:10.1007/s00431-019-03556-9.; Lenk C., Duttge G. Ethical and legal framework and regulation for off-label use: European perspective. Ther Clin Risk Manag. 2014;10:537-46. DOI:10.2147/TCRM.S40232.; Aronson J.K., Ferner R.E. Unlicensed and off-label uses of medicines: definitions and clarification of terminology. Br J Clin Pharmacol. 2017;83:2615-25. DOI:10.1111/bcp.13394.; Stafford R.S. Regulating off-label drug use: rethinking the role of the FDA. N Engl J Med. 2008;358(14):1427-9. DOI:10.1056/NEJMp0802107.; França K., Litewka S. Controversies in off-label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies. Int J Dermatol. 2019;58:788-94. DOI:10.1111/ijd.14222.; Oliphant C.S., Owens R.E., Bolorunduro O.B., Jha S.K. Ivabradine: A Review of Labeled and Off-Label Uses. Am J Cardiovasc Drugs. 2016;16:337-47. DOI:10.1007/s40256-016-0178-z.; Schulze V., Steiner S., Hennersdorf M., Strauer B.E. Ivabradine as an alternative therapeutic trial in the therapy of inappropriate sinus tachycardia: a case report. Cardiology. 2008;110:206-8. DOI:10.1159/000111931.; Retegui G., Quintero M., Ruiz-Borrell M., Revello A. Ivabradine as a treatment option for inappropriate sinus tachycardia. Rev Esp Cardiol. 2009;62:576-88. DOI:10.1016/s1885-5857(09)71843-2.; Winum P.F., Cayla G., Rubini M., et al. A case of cardiomyopathy induced by inappropriate sinus tachycardia and cured by ivabradine. PACE. 2009;32:942-4. DOI:10.1111/j.1540-8159.2009.02414.x.; Settle A., Martino A., Lioy E., Calo L. Efficacy of ivabradine in a case of inappropriate sinus tachycardia and ventricular dysfunction. J Cardiovasc Electrophysiol. 2010;21:815-7. DOI:10.1111/j.1540-8167.2009.01699.x.; Goyal V.K., Godara S., Sadasukhi T.C., Gupta H.L. Management of inappropriate sinus tachycardia with ivabradine in a renal transplant recipient. Drug Discov Ther. 2014;8:132-3. DOI:10.5582/ddt.2014.01023.; Zellerhoff S., Hinterseer M., Felix Krull B., et al. Ivabradine in patients with inappropriate sinus tachycardia. Naunyn Schmiedebergs Arch Pharmacol. 2010;382(5-6):483-6. DOI:10.1007/s00210-010-0565-y.; Calo L., Rebecchi M., Sette A., et al. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm. 2010;7:1318-23. DOI:10.1016/j.hrthm.2010.05.034.; Benezet-Mazuecos J., Rubio J.M., Farre J., et al. Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients. PACE. 2013;36:830-6. DOI:10.1111/pace.12118.; Ptaszynski P., Kaczmarek K., Ruta J., et al. Ivabradine in the treatment of inappropriate sinus tachycardia in patients after successful radiofrequency catheter ablation of atrioventricular node slow pathway. PACE. 2013;36:42-9. DOI:10.1111/pace.12018; Boeken U., Assmann A., Mehdiani A., et al. Ivabradine in patients with inappropriate sinus tachycardia after cardiac surgery: alternative to b-blockers? Thorac Cardiovasc Surg. 2012;60:119. DOI:10.1055/s-0031-1297766.; Cappato R., Castelvecchio S., Ricci C., et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol. 2012;60:1323-9.DOI:10.1016/j.jacc.2012.06.031.; Ptaszynski P., Kaczmarek K., Ruta J., et al. Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy. Europace. 2013;15:116—121. DOI:10.1093/europace/eus204.; Ptaszynski P., Kaczmarek K., Ruta J., et al. Ivabradine in combination with metoprolol succinate in the treatment of inappropriate sinus tachycardia. J Cardiovasc Pharmacol Ther. 2013;18:338-44. DOI:10.1177/1074248413478172.; Sheldon R.S., Grubb B.P. II, Olshansky B., et al. 2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope. Heart Rhythm. 2015;12:e41-63. DOI:10.1016/j.hrthm.2015.03.029.; Frattarelli D.A., Galinkin J.L., Green T.P., et al. American Academy of Pediatrics Committee on Drugs. Off-label use of drugs in children. Pediatrics. 2014;133:563-7. DOI:10.1542/peds.2013-4060.; Connolly H.M., Crary J.L., McGoon M.D., et al. Valvular heart disease associated with fenfluraminephentermine. N Engl J Med. 1997;337:581-8. DOI:10.1056/NEJM199708283370901.; Friedman M.A., Woodcock J., Lumpkin M.M., et al. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA. 1999;281:1728-34. DOI:10.1001/jama.281.18.1728.; Cheng W.H., Chao T.F., Lin Y.J., et al. Low-Dose Rivaroxaban and Risks of Adverse Events in Patients With Atrial Fibrillation. Stroke. 2019;50:2574-7. DOI:10.1161/STROKEAHA.119.025623.; Paciaroni M., Agnelli G., Caso V., et al. Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. Stroke. 2019;50(8):2168-74. DOI:10.1161/STROKEAHA.119.025350.; Santos J., António N., Rocha M., Fortuna A. Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: A systematic review. Br J Clin Pharmacol. 2019 Oct 20. DOI:10.1111/bcp.14127. [Epub ahead of print].; Noel N., Dutasta F., Costedoat-Chalumeau N., et al. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev. 2015;14(8):680-5. DOI:10.1016/j.autrev.2015.03.007.; Cohen H., Hunt B.J., Efthymiou M., et al.; RAPS trial investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 2016;3(9):e426-436. DOI:10.1016/S2352-3026(16)30079-5.; Ordi-Ros J., Sáez-Comet L., Pérez-Conesa M., et al. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial. Ann Intern Med 2019 Oct 15. DOI:10.7326/M19-0291. [Epub ahead of print].; Konstantinides S.V., Meyer G., Becattini C., et al.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603. DOI:10.1093/eurheartj/ehz405.; Pokorney S.D. American College of Cardiology Webpage, AHA 2019 Presentation Slides for the RENAL-AF Trial [cited by April 01, 2020]. Available from: https://www.acc.org/education-andmeetings/image-and-slide-gallery/media-detail?id=469e5bd88-f4d2bb8ec183e71521637.; Reinecke H., Jurgensmeyer S., Engelbertz C., et al. Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: The AXADIA-AFNET 8 study. BMJ Open. 2018;8(9):e022690. DOI:10.1136/bmjopen-2018-022690.; Noseworthy P.A., Kaufman E.S., Chen L.Y., et al. Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap: A Scientific Statement From the American Heart Association. Circulation. 2019;140(25):e944-e963. DOI:10.1161/CIR.0000000000000740.; Lopes R.D., Alings M., Connolly S.J., et al. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. Am Heart J. 2017;189:137-45. DOI:10.1016/j.ahj.2017.04.008.; Kirchhof P., Blank B.F., Calvert M., et al. Probing oral anticoagulation in patients with atrial high rate episodes: rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J. 2017;190:12-8. DOI:10.1016/j.ahj.2017.04.015.; Hart R.G., Sharma M., Mundl H., et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med. 2018;378(23):2191-201. DOI:10.1056/NEJMoa1802686.; Diener H.C., Sacco R.L., Easton J.D., et al. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. N Engl J Med. 2019;380(20):1906-17. DOI:10.1056/NEJMoa1813959.; Busko M. Rivaroxaban May Reduce Stroke After ESUS With Large Left Atrium [cited by April 01, 2020]. Available from: https://www.medscape.com/viewarticle/904151.; Kamel H., Longstreth W.T. Jr, Tirschwell D.L., et al. The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods. Int J Stroke. 2019;14(2):207-14. DOI:10.1177/1747493018799981.; Ay C., Pabinger I., Cohen A.T. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost. 2017;117:219-30. DOI:10.1160/TH16-08-0615.; Lyman G.H., Bohlke K., Falanga A., American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract. 2015;11:e442-e444. DOI:10.1200/JOP.2015.004473.; Kearon C., Akl E.A., Ornelas J., et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315-52. DOI:10.1016/j.chest.2015.11.026.; Lee A.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146- 53. DOI:10.1056/NEJMoa025313.; Lee A.Y.Y., Kamphuisen P.W., Meyer G., Bauersachs R., et al.; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015;314:677-86. DOI:10.1001/jama.2015.9243.; Raskob G.E., van Es N., Verhamme P., et al.; Hokusai VTE Cancer Investigators. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018;378:615-24. DOI:10.1056/NEJMoa1711948.; Agnelli G., Becattini C., Meyer G., et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020 Mar 29. DOI:10.1056/NEJMoa1915103. [Epub ahead of print].; https://www.rpcardio.com/jour/article/view/2181

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2181
https://doi.org/10.20996/1819-6446-2020-04-14

Antithrombotic therapy in patients with coronary heart disease and atrial fibrillation after direct myocardial revascularization ; Антитромботическая терапия у пациентов с ишемической болезнью сердца и фибрилляцией предсердий после прямой реваскуляризации миокарда

Συγγραφείς: M. A. Kirgizova, O. R. Eshmatov, Yu. I. Bogdanov, R. E. Batalov, S. V. Popov, М. А. Киргизова, О. Р. Эшматов, Ю. И. Богданов, Р. Е. Баталов, С. В. Попов

Πηγή: Siberian Journal of Clinical and Experimental Medicine; Том 35, № 4 (2020); 49-56 ; Сибирский журнал клинической и экспериментальной медицины; Том 35, № 4 (2020); 49-56 ; 2713-265X ; 2713-2927

Θεματικοί όροι: дабигатран, atrial fibrillation, ischemic heart disease, direct oral anticoagulants, фибрилляция предсердий, ишемическая болезнь сердца, прямые пероральные антикоагулянты, ривароксабан, апиксабан

Περιγραφή αρχείου: application/pdf

Relation: https://www.sibjcem.ru/jour/article/view/1073/576; Haim M., Hoshen M., Reges O., Rabi Y., Balicer R., Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non valvular atrial fibrillation. J. Am. Heart Assoc. 2015;4(1):e001486. DOI:10.1161/JAHA.114.001486.; Lippi G., Sanchis-Gomar F., Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int. J. Stroke. 2020;1747493019897870. DOI:10.1177/1747493019897870.; Valgimigli M., Bueno H., Byrne R., Collet J.-P., Costa F., Jeppsson A. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association of Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2018;39(3):213–260. DOI:10.1093/eurheartj/ehx419.; Бокерия Л.А., Аронов Д.М., Барбараш О.Л., Бубнова М.Г., Князева Т.А., Лямина Н.П. и др. Российские клинические рекомендации. Коронарное шунтирование больных ишемической болезнью сердца: реабилитация и вторичная профилактика. CardioСоматика. 2016;7(3–4):5–71.; Vohra H.A., Whistance R., Modi A., Ohri S.K. The inflammatory response to miniaturised extracorporeal circulation: a review of the literature. Mediators of Inflammation. 2009;707042. DOI:10.1155/2009/707042.; Zheng A.S.Y., Churilov L., Colley R.E., Goh C., Davis S.M., Yan B. Association of aspirin resistance with increased stroke severity and infarct size. JAMA Neurol. 2013;70(2):208–213. DOI:10.1001/jamaneurol.2013.601.; Мартынов А.И., Акатова Е.В., Урлаева И.В., Николин О.П. Истинная резистентность и псевдорезистентность к аспирину. Рациональная Фармакотерапия в Кардиологии. 2013;9(4):301–305. DOI:10.20996/1819-6446-2013-9-3-301-305.; Wang Y., Chen S., Shi J.W., Dong W.-G. Benefit and Safety of Dual Antiplatelet Therapy after Coronary Artery Bypass Grafting for Off-pump CABG: A Systematic Review and Meta-analysis. British Journal of Medicine and Medical Research. 2015:9(11):1–15. DOI:10.9734/BJMMR/2015/19433.; Aryana A., Singh S.K., Singh S.M., O’Neill P.G., Bowers M.R., Allen S.L. et al. Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization. Heart Rhythm. 2015;12(7):1431–1437. DOI:10.1016/j.hrthm.2015.03.028.; Chatterjee S., Alexander J.C., Pearson P.J., Feldman T. Left atrial appendage occlusion: Lessons learned from surgical and transcatheter experiences. Ann. Thorac. Surg. 2011;92(6):2283–2292. DOI:10.1016/j.athoracsur.2011.08.044.; Budera P., Straka Z., Osmančík P., Vaněk T., Jelínek S., Hlavička J. et al. Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre study. Eur. Heart J. 2012;33(21):2644–2652. DOI:10.1093/eurheartj/ehs290.; Двойная антитромбоцитарная терапия при ишемической болезни сердца: обновленная версия 2017 года. Российский кардиологический журнал. 2018;23(8):113–163. DOI:10.15829/1560-4071-2018-8-113-163.; Сулимов В.А., Голицын С.П., Панченко Е.П., Попов С.В., Ревишвили А.Ш., Шубик Ю.В. и др. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. Российский кардиологический журнал. 2013;4(102):1–100.; Сулимов В.А., Напалков Д.А., Соколова А.А. Сравнительная эффективность и безопасность новых пероральных антикоагулянтов. Рациональная Фармакотерапия в Кардиологии. 2013;9(4):433–438.; Tabl M.A. Безопасность и эффективность комбинации ривароксабана и клопидогрела для лечения фибрилляции предсердий у пациентов с острым коронарным синдромом. Международный журнал сердца и сосудистых заболеваний. 2017;5(16):22–30.; Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 2020;ehaa612. DOI:10.1093/eurheartj/ehaa612.; https://www.sibjcem.ru/jour/article/view/1073

Διαθεσιμότητα: https://www.sibjcem.ru/jour/article/view/1073
https://doi.org/10.29001/2073-8552-2020-35-4-49-56